Preparations with short amphiphilic peptides for cosmesis

Amphiphilic peptides with alternating charged and hydrophobic residues self-assemble into fibril formations, addressing the limitations of existing cosmetically applied formulations by enhancing skin hydration and antimicrobial efficacy while maintaining biocompatibility.

WO2026241591A1PCT designated stage Publication Date: 2026-11-19GEL4MED INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028287
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing cosmetically applied formulations lack the ability to effectively self-assemble into stable structures that enhance skin hydration, bioactivity, and tissue penetration while maintaining biocompatibility and antimicrobial function, particularly with shorter peptide sequences.

Method used

Development of amphiphilic peptides with alternating charged and hydrophobic residues that self-assemble into fibril formations, forming a protective biomatrix for topical application, enhancing skin hydration and cellular regeneration with antimicrobial properties.

Benefits of technology

The amphiphilic peptides achieve stable self-assembly, improve skin hydration, promote cellular regeneration, and exhibit antimicrobial efficacy, even at low concentrations, while maintaining biocompatibility and avoiding uncontrolled aggregation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028287_19112026_PF_FP_ABST
    Figure US2026028287_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Preparations containing one or more peptides having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the one or more peptides self-assembling into a fibril formation are provided. Preparations containing one or more peptides having a sequence of [AY]N, [YA]M, Y[AY]N, or A[YA]M. where A is 1-3 amino acids selected from one or more of basic, neutral, aliphatic, aromatic, amphipathic, polar, and charged amino acids, Y is 1-3 hydrophobic amino acids, and N and M are between 1 and 10, the one or more peptides being substantially free of a turn sequence are also provided. Methods of providing cosmesis including administering an effective amount of a preparation are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Docket No. G2093-7014WO

[0002] PREPARATIONS WITH SHORT AMPHIPHILIC PEPTIDES FOR COSMESIS

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Serial No. 63 / 805,521 titled “PREPARATIONS WITH SHORT AMPHIPHILIC PEPTIDES FOR COSMESIS” filed May 14, 2025, which is herein incorporated by reference in its entirety for all purposes.

[0004] SEQUENCE LISTING

[0005] The instant application contains a Sequence Listing which has been submitted electronically in XML (extensible Markup Language) and is hereby incorporated by reference in its entirety. Said XML copy, created on May 14, 2026, is named G2093-7014WO_SL.xml.

[0006] FIELD OF TECHNOLOGY

[0007] Aspects and embodiments disclosed herein are directed to topical administration of amphiphilic peptide formulations. In particular, aspects and embodiments are directed to amphiphilic peptide formulations and methods of cosmesis.

[0008] SUMMARY

[0009] In accordance with one aspect, there is provided a preparation comprising one or more peptides having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the one or more peptides being configured to selfassemble into a fibril formation, in a cosmetically acceptable carrier.

[0010] In accordance with another aspect, there is provided a preparation comprising one or more peptides having a sequence of [AY]N, [YA]M. Y[AY]N, or A[YA]M, where A is 1-3 amino acids selected from one or more of basic, neutral, aliphatic, aromatic, amphipathic, polar, and charged amino acids, Y is 1-3 hydrophobic amino acids, and N and M are between 1 and 10, the one or more peptides being substantially free of a turn sequence, in a cosmetically acceptable carrier.

[0011] In accordance with another aspect, there is provided a preparation comprising one or more peptides having a sequence of any of SEQ ID NOS: 1-73 and 107, one or more peptidesDocket No. G2093-7014WO

[0012] having a sequence having 1 -4 substitutions of any of SEQ ID NOS: 1 -73 and 107, or one or more peptides having a sequence of any of SEQ ID NOS: 1-73 and 107 or a sequence having 1-4 substitutions of any of SEQ ID NOS: 1-73 and 107 and further having a modification; in a cosmetically acceptable carrier.

[0013] In some embodiments, the one or more peptides comprise 6-18 amino acid residues. In some embodiments, the hydrophobic amino acid residues are independently selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, tryptophan, and combinations thereof.

[0014] In some embodiments, the charged amino acid residues are independently selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, cysteine, arginine, lysine, histidine, aspartic acid, glutamic acid, and combinations thereof.

[0015] In some embodiments, the charged amino acid residues are positively charged amino acid residues.

[0016] In some embodiments, the charged amino acid residues are negatively charged amino acid residues.

[0017] In some embodiments, A is 1-3 uncharged polar amino acid residues.

[0018] In accordance with another aspect, there is provided a preparation comprising a fragment of a peptide of any of SEQ ID NOS: 75-97; a fragment of a peptide having a sequence having 1-4 substitutions of any of SEQ ID NOS: 75-97; or a fragment of a peptide of any of SEQ ID NOS: 75-97 or a fragment of a peptide having a sequence having 1-4 substitutions of any of SEQ ID NOS: 75-97 and further having a modification, in a cosmetically acceptable carrier.

[0019] In some embodiments, the fragment of the peptide of any of SEQ ID NOS:75-97 is a peptide having a sequence of SEQ ID NO: 74.

[0020] In some embodiments, the one or more peptides further comprise a modification.

[0021] In some embodiments, the modification is a bioactive functional group, linker, spacer, or terminal modification.

[0022] In some embodiments, the modification is a bioactive functional group having a sequence of any of SEQ ID NOS. 98-106.

[0023] In some embodiments, the modification is a terminal modification selected from acetylation, amidation, free carboxyl, PEGylation, lipidation, glycosylation, cyclization, and combinations thereof.Docket No. G2093-7014WO

[0024] In some embodiments, the one or more peptides have a free amine at the N-terminus, a free carboxyl group at the C-terminus, or both.

[0025] In some embodiments, the one or more peptides comprises at least one glutamic acid residue.

[0026] In some embodiments, the preparation is formulated for topical administration.

[0027] In some embodiments, the preparation is formulated as an aqueous solution, gel. lotion, ointment, cream, serum, oil, salve, and / or solid.

[0028] In some embodiments, the preparation is formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe.

[0029] In some embodiments, the preparation is formulated as a film, membrane, sheet, barrier dressing, or impregnated material.

[0030] In some embodiments, the preparation consists of or consists essentially of the one or more peptides in the cosmetically acceptable carrier.

[0031] In some embodiments, the preparation is substantially free of one or more of preservatives, fillers, bulking agents, fragrances, or colorants.

[0032] In some embodiments, the preparation is formulated for parenteral administration.

[0033] In some embodiments, the one or more peptides are at least 70% purified.

[0034] In some embodiments, the one or more peptides are at least 80% purified.

[0035] In some embodiments, the one or more peptides are at least 95% purified.

[0036] In some embodiments, the one or more peptides comprise acetate and / or citrate counterions.

[0037] In some embodiments, the one or more peptides are free of chloride counterions.

[0038] In some embodiments, the preparation comprises between 0.01% w / v and 10.0% w / v of the one or more peptides.

[0039] In some embodiments, the preparation comprises between 0.25% w / v and 0.5% w / v of the one or more peptides.

[0040] In some embodiments, the one or more peptides have a net charge of from -10 to +11. In some embodiments, the one or more peptides have a net charge of +3 to +4.

[0041] In some embodiments, the preparation is sterile.

[0042] In some embodiments, the preparation is sterilized by autoclave or steam sterilization. In some embodiments, the preparation has a pH between 3 and 8.Docket No. G2093-7014WO

[0043] In some embodiments, the preparation has a pH between 5.5 and 6.5.

[0044] In some embodiments, the preparation further comprises an effective amount of one or more of a cationic or anionic salt, a dermatologically compatible buffer, a zwitterionic buffer, an organic acid and / or salt thereof, a chelating buffer, or a combination thereof.

[0045] In accordance with another aspect, there is provided a method of providing cosmesis, comprising administering an effective amount of a preparation comprising one or more peptides to a target tissue of a subject.

[0046] In some embodiments, administration improves skin integrity, improves skin surface topology, reduces or prevents degradation of collagen in skin of the subject or increases collagen content in skin of the subject, reduces or prevents inflammation in skin or a hair follicle, prevents, limits, or inhibits progression of an appearance or effect of aging in the skin, prevents, limits, or inhibits skin inflammation, prevents, limits, or inhibits injury to skin integrity or condition, substantially maintains a state of skin integrity or condition, prevents, limits, or inhibits a topographical change of a cutaneous layer of skin.

[0047] In some embodiments, administration treats or prevents skin wrinkles and / or treats or prevents a change in skin pigmentation.

[0048] In some embodiments, administration promotes firmness, hydration, elasticity, radiance, tone evenness, visual smoothness, or tactile smoothness associated with skin of the subject.

[0049] In some embodiments, the target tissue is an integumental tissue selected from an epidermal, dermal, or hypodermal tissue.

[0050] In some embodiments, the integumental tissue is on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.

[0051] In some embodiments, the preparation is administered topically.

[0052] BRIEF DESCRIPTION OF THE DRAWINGS

[0053] The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:Docket No. G2093-7014WO

[0054] FIG. 1 includes images of cellular morphology of MEF DI cells after treatment with peptide formulations, according to one embodiment;

[0055] FIG. 2 is a graph showing adjusted cell viability (%) of MEF DI cells incubated with peptides, according to one embodiment;

[0056] FIG. 3 A is a chromatogram of a serum sample containing 0.25% w / v peptides, according to one embodiments;

[0057] FIG. 3B is a chromatogram of the serum sample of FIG. 3A after heating to 121 °C for 30 min, according to one embodiment;

[0058] FIG. 4 is a line drawing of a photograph of the preparation provided in an end-use container, according to one embodiment;

[0059] FIG. 5A includes graphs showing CFU enumeration of prepared cultures of A) bacteria and B) fungus;

[0060] FIG. 5B includes graphs showing microbial recovery between control and test plates for A) bacteria and B) fungus;

[0061] FIG. 6 is a photograph showing absence of microbial growth on negative control plates and test article plates

[0062] FIG. 7 includes graphs of bacterial input and bacterial control of prepared cultures of test organism;

[0063] FIG. 8A includes photographs of agar plates of MRSA and P. aeruginosa incubated with the test article at various concentrations; and

[0064] FIG. 8B includes a graph of bacterial recovery showing that no growth was observed on the agar plates of FIG. 8A at 24 hours after incubation with the test article at various concentrations.

[0065] DETAILED DESCRIPTION

[0066] Cosmesis refers to the preservation, restoration, or enhancement of physical appearance, particularly in medical or surgical contexts. For instance, in surgery, cosmesis may refer to compositions and methods used to minimize scarring and improve the aesthetic results of a procedure. In dermatology, cosmesis may refer to compositions and methods to improve skin appearance, such as texture and tone. The compositions disclosed herein may be used in methods of cosmesis.Docket No. G2093-7014WO

[0067] Preparations comprising peptides are disclosed herein. The peptide formulations may form a protective moisturizing biomatrix that enhances skin hydration and supports cell renewal.

[0068] The peptides may be amphiphilic, having a plurality of charged amino acid residues and hydrophobic residues arranged in a substantially alternating pattern. The peptides disclosed herein have surprisingly been found to maintain self-assembly while optimizing bioactivity, tissue penetration, and structural stability. In particular, the peptides may be designed to selfassemble into an optimized higher order structure showing excellent stability, improve hydration and bioactivity for cellular regeneration, maintain a desired charge for cellular interaction and antimicrobial function, and have a selected degree of hydrophobicity, improving self-assembly and biocompatibility.

[0069] Select Definitions

[0070] The formulations disclosed herein may be cytocompatible. Cytocompatibility, defined herein, means that the formulation must not be adverse to desired cells, in vitro and / or in vivo. Adversity to cells may be measured by cytotoxicity, cell adhesion, proliferation, phenotype maintenance, and / or differentiation of progenitor cells.

[0071] The formulations described herein may be biocompatible. “Biocompatible,” defined herein, means that a material does not cause a significant immunological and / or inflammatory response if placed in vivo. Biocompatibility may be measured according to International Organization for Standardization (ISO) 10993 standards.

[0072] The peptides may be biodegradable affording non-toxic species. The peptides may be proteolytically biodegradable. “Proteolytic” biodegradation, defined herein, refers to local degradation of the material in response to the presence of cell-derived proteases and / or gradual degradation with the proliferation of cells. The peptides may be hydrolytically biodegradable. “Hydrolytic” biodegradation, defined herein, refers to polymer degradation without assistance from enzyme under biologic conditions.

[0073] The peptides may be bioresorbable. Bioresorbable, defined herein, means that the peptides break down into remnants that are natural products readily absorbed into the body, resulting in complete loss of original mass.

[0074] The peptides and / or other materials disclosed herein may be referred to as having one or more physiological properties. As disclosed herein, physiological properties or values refer toDocket No. G2093-7014WO

[0075] those which are compatible with the subject. In particular, physiological properties or values may refer to those which are compatible with a particular target tissue. In certain embodiments, physiological properties or values may refer to those which are substantially similar to the properties or values of the target tissue. Physiological properties may include one or more of pH value, temperature, net charge, water content, stiffness, and others.

[0076] As used herein, “treatment” of an injury, condition, or disease refers to reducing the severity or frequency of at least one symptom of that injury, condition, or disease, compared to a similar but untreated subject. Treatment can also refer to halting, slowing, or reversing the progression of an injury, condition, or disease, compared to a similar but untreated subject.

[0077] Treatment may comprise addressing the root cause of the injury, condition, or disease and / or one or more symptoms. “Management” of an injury, condition, or disease may refer to reducing the severity or frequency of at least one symptom of that injury, condition, or disease, to a tolerable level, as determined by the subject or a health care provider.

[0078] As used herein an effective amount refers to a dose or amount sufficient to achieve a desired result. For example, the effective amount may refer to a concentration sufficient to provide desired properties. An effective amount may refer to a dose sufficient to prevent advancement, or to cause regression of an injury, condition, or disease, or which is capable of relieving a symptom of an injury, condition, or disease, or which is capable of achieving a desired result. An effective amount can be measured, for example, as a concentration of peptide or other component in the preparation, e.g., a solution, or buffer.

[0079] Administered “in combination,” as used herein, means that two (or more) different treatments are delivered to the subject during the course of the subject’s affliction with the injury, condition, or disease, e.g., the preparation is delivered with a second agent after the subject has been diagnosed with the condition, injury, or disease and before the condition, injury, or disease has been cured or eliminated. In certain embodiments, administration in combination means the preparation additionally comprises one or more second agent. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap. This is sometimes referred to herein as “simultaneous” or "concomitant” or “concurrent delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. This is sometimes referred to herein as “successive” or “sequential delivery.”Docket No. G2093-7014WO

[0080] In embodiments of either case, the treatment may be more effective because of combined administration. For example, the second agent may be a more effective, e.g., an equivalent effect is seen with less of the second agent, or the second agent reduces symptoms to a greater extent, than would be seen if the second agent were administered in the absence of the preparations disclosed herein, or the analogous situation is seen with the preparation. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (z.e., synergistic). The delivery can be such that an effect of the administration of the preparation is still detectable when the second agent is delivered. In some embodiments, one or more treatment may be delivered prior to diagnosis of the subject with the condition, injury, or disease.

[0081] As used herein, a subject may include an animal, a mammal, a human, a non-human animal, a livestock animal, or a companion animal. The term “subject” is intended to include human and non-human animals, for example, vertebrates, large animals, and primates. In certain embodiments, the subject is a mammalian subject, and in particular embodiments, the subject is a human subject. Although applications with humans are clearly foreseen, veterinary applications, for example, with non-human animals, are also envisaged herein. The term “non-human animals” of the disclosure includes all vertebrates, for example, non-mammals (such as birds, for example, chickens; amphibians; reptiles) and mammals, such as non-human primates, domesticated, and agriculturally useful animals, for example, sheep, dog, cat, cow, pig, rat, among others. The term “non-human animals” includes research animals, for example, for example, mouse, rat, rabbit, dog, cat, pig, among others.

[0082] Throughout this disclosure, formulation may refer to a composition or preparation or product.

[0083] Preparations and formulations disclosed herein may generally be referred to as peptide preparations. The peptide preparation may include a cytocompatible and / or biocompatible solution. The preparation may include a buffer. While reference is made to a solution, it should be understood that the preparation may be in the form of a liquid, gel, or solid particle. In certain embodiments, for example, the preparation may be in the form of the assembled hydrogel. In other embodiments, the preparation may be in the form of a lyophilized powder.Docket No. G2093-7014WO

[0084] The peptide preparation may further include one or more bioactive components for tissue engineering, such as, functionalized peptides, cells, media, serum, collagen and other structureimparting components, antibodies and antigens, bioactive small molecules, and other bioactive drugs. “Bioactivity” as described herein refers to the ability of a compound to impart a biological effect.

[0085] “Self-assembling” peptides include such peptides which, typically, after being exposed to a stimulus, will assume a desired secondary structure. Certain peptides disclosed herein may self-assemble into a higher order structure, for example a three-dimensional network and, consequently, a hydrogel. The self-assembled hydrogel may contain peptides in a tertiary and / or quaternary structure through charge screening, hydrophobic, and disulfide interactions. Peptides have been observed to self-assemble into helical ribbons, nanofibers, nanotubes and vesicles, surface-assembled structures and others.

[0086] “Disassembly” of the peptides may refer to the ability of the peptide to assume a lower order structure after being exposed to a stimulus. Disassembly may also refer to the ability of the physically crosslinked peptide to temporarily break hydrophobic and disulfide bonds to assume a lower order structure after being exposed to a stimulus. For example, a tertiary structure protein may disassemble into a secondary structure protein, and further disassemble into a primary structure peptide. In accordance with certain embodiments, self-assembly and disassembly of the peptide may be reversible.

[0087] As used herein, a “cosmetically acceptable carrier” may refer to any safe or approved vehicle or diluent for delivery of the active agent, e.g., peptide, to a target tissue. The cosmetically acceptable earner may be a dermatologically safe or approved vehicle or diluent for delivery of the active agent to skin. The cosmetically acceptable carrier may be an inert vehicle or diluent. Exemplary cosmetically acceptable carriers include water or water-based mixtures, oils or oil-based mixtures, emulsions, alcohol-water solutions, polymers or gels, solvents, silicones, solid or powder-based carriers, biodegradable or natural carriers, and other standard cosmetic bases.

[0088] Self-Assembling Peptides

[0089] The peptides disclosed herein may comprise a self-assembling peptide capable of forming a hydrogel. Hydrogels are a class of materials that have significant promise for use inDocket No. G2093-7014WO

[0090] soft tissue and bone engineering. The general characteristic of hydrogels that make them important materials for these applications are their well hydrated, porous structure. Hydrogels may be designed to be compatible with the adhesion and proliferation of various cell types, e.g., fibroblasts and osteoblasts, making them potential tissue engineering scaffolds for generating connective tissue, such as cartilage, tendons, and ligaments, and bone.

[0091] Self-assembling peptides may assemble responsive to certain environmental conditions, e.g., pH, temperature, net charge, exposure to light, applied sound wave, or presence or absence of environmental factors. The environmental conditions may occur upon administration to a subject or by combination with a buffer. In other embodiments, the peptides may assemble spontaneously in solution under neutral pH level. The peptides may assemble spontaneously in solution under physiological conditions and / or in the presence of a cation and / or anion.

[0092] The inventors surprisingly found that the short peptides disclosed herein, for example, peptides having less than 20 amino acid residues, less than 18 amino acid residues, less than 16 amino acid residues, less than 14 amino acid residues, less than 12 amino acid residues, or even less than 10 amino acid residues, self-assemble into a higher order structure, in particular even when the peptides lack a turn sequence. Certain exemplary peptides disclosed herein may have, for example, 6-18 amino acid residues, 8-16 amino acid residues, 10-14 amino acid residues, or any range of residues between 2 and 19.

[0093] In the context of peptide secondary structure, a turn sequence is a series of amino acid residues in the peptide that provides a folding motif. The turn sequence may provide, for example, a P-turn-forming motif. The turn sequence may be formed of several, e.g., 3-5, amino acid residues that induce a hairpin bend. Larger peptides having a turn sequence typically fold into an amphiphilic -hairpin. In the folded state, the larger peptides self-assemble via lateral and facial associations of the hairpins to form a non-covalently crosslinked hydrogel containing p-sheet rich fibrils, as described in U.S. Patent Application Publication No. 2024 / 0366717, titled “Antimicrobial matrix formed from peptide hydrogels,” which is incorporated herein by reference in its entirety for all purposes.

[0094] It was surprising and unexpected that the peptides disclosed herein, for example, those being free of a turn sequence, are capable of self-assembly without relying on hairpin formation, in particular, capable of controlled self-assembly into a nanofiber network. In addition, it was surprising and unexpected that the peptides disclosed herein avoid uncontrolled aggregation,Docket No. G2093-7014WO

[0095] lateral bundling, or visible particulates when self-assembled. For instance, the peptides described herein undergo controlled self-assembly into a nanofiber network, and are substantially free of uncontrolled lateral bundling or visible particulates after storage at 15 to 25 °C for at least 24 months. These results are surprising and unexpected. Certain shorter peptides disclosed herein self-assemble into a fibril formation, e.g., a random fibril formation.

[0096] Prior to designing the short peptides disclosed herein, it was believed that self-assembling peptides required at least 16-20 amino acid residues or more and / or a sequence that selfassembles into a P-sheet formation to form a stable hydrogel. The short peptides disclosed herein surprisingly achieve self-assembly to form a stable hydrogel with shorter sequences and / or without a turn sequence. Thus, it is surprising that the peptides disclosed herein are capable of forming a hydrogel. It is also surprising that a preparation having less than 0.50% w / v of the peptide, for example, 0.50% - 0.25% w / v, or about 0.25% w / v, is semi- viscous. Additionally, it is believed that the peptides disclosed herein are efficacious against gram-negative and grampositive cutaneous pathogens at a concentration as low as about 0.25% w / v or between 0.50% -0.25% w / w.

[0097] The inventors also surprisingly found that the short peptides disclosed herein exhibit antimicrobial efficacy. It is surprising that despite their short length, the peptides disclosed herein were found to retain antimicrobial function and enhanced cellular regeneration in vitro, which is typically only observed with longer p-sheet peptides. The short peptides disclosed herein are believe to exhibit a synergistic effect, enabled by improved skin penetration due to small size, balanced charge for low cytotoxicity, and antimicrobial efficacy.

[0098] The peptides disclosed herein may assemble into a nano-porous tertiary structure. As disclosed herein, the nano-porous structure is a three-dimensional matrix containing pores having an average size of 1-1000 nm. The pores or voids may constitute between 10% and 90% of the three-dimensional matrix by volume. For example, the pores or voids may constitute 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the three-dimensional matrix by volume. The pores may be permeable and allow diffusion of liquid and / or gas. The nano-porous structure is constructed by physical crosslinks, allowing ionic bonds to be broken and reformed upon asserted stress. These nano-porous structure may allow for cells to attach and / or migrate through the matrix. The nano-porous structure may also mimic the endogenous extra-cellular matrix environment of tissues and, optionally, be selected to mimic a specific tissue.Docket No. G2093-7014WO

[0099] The peptides disclosed herein may be designed to be substantially amphiphilic when assembled into the tertiary structure. “Amphiphilic” molecules, e.g., macromolecules or polymers, as disclosed herein, typically contain hydrophobic and hydrophilic components.

[0100] Peptide amphiphiles are one exemplary class of amphiphilic molecules. Peptide amphiphiles are peptide-based molecules that typically have the tendency to self-assemble into high-aspect-ratio nanostructures under certain conditions. The exemplary conditions may comprise selected pH, temperature, and ionic strength values. One particular type of peptide amphiphiles comprise alternating charged, neutral, and hydrophobic residues, in a repeated pattern, for example, as disclosed herein.

[0101] The peptides may have a net charge of from -10 to +11, for example, -8 to +8, or -4 to +4 at a physiological pH, e.g., pH 7.4. In some embodiments, the peptides may be cationic. Cationic peptides may have a net charge of from +2 to +11, for example, +2 to +5, +3 to +4, +5 to +7, or +7 to +9. The peptides may have a charge of about +2, +3, +4, +5, +6, +7, +8, +9, +10, or +11 at pH 7.4.

[0102] In other embodiments, the peptides may be substantially neutral. Substantially neutral peptides may have a net charge of -1 to +1, -1 to 0, or 0 to +1, for example, -1, 0, or +1.

[0103] In other embodiments, the peptides may be anionic. Anionic peptides may have a net charge of from -10 to -2, for example, -10 to -7, -7 to -5, -4 to -3, or -5 to -2, for example, -7, -6, -5, -4. -3, -2, -1, or 0.

[0104] Peptide Sequences

[0105] Preparations comprising one or more peptides are disclosed herein. In some embodiments, the peptides in the preparation may be substantially homogeneous. For instance, the preparation may have a plurality of peptides of the same sequence. In other embodiments, the peptides in the preparation may be substantially heterogeneous. For instance, the preparation may have a plurality of peptides of two or more sequences.

[0106] The preparation may comprise one or more peptide of any of SEQ ID NOS: 1-73 and 107. The preparation may comprise one or more peptide having a sequence having one or more substitutions, e.g., 1-4 substitutions or 1, 2, 3, or 4 substitutions of any of SEQ ID NOS: 1-73 and 107. The one or more substitution may be selected to improve self-assembly, bioactivity, and / or therapeutic activity of the peptide. The preparation may comprise one or more peptide of any ofDocket No. G2093-7014WO

[0107] SEQ ID NOS: I -73 or 107 or one or more peptide having one or more substitutions of SEQ ID NOS: 1-73 or 107 further having one or more modification, such as including a bioactive functional group, linker, spacer, or terminal modification.

[0108] In some embodiments, the peptides may comprise a fragment of a peptide of any of SEQ ID NOS: 75-97. Each peptide fragment may contain 10-90% of the amino acid residues of the peptide of SEQ ID NOS: 75-97, for example, 10-75%, 10-50%, or 10-25%. The peptide of SEQ ID NO: 74 is one exemplary fragment of the peptide of SEQ ID NO: 76. The peptides may comprise a fragment of the self-assembling peptides disclosed in and / or prepared by the methods disclosed in any of U.S. Patent Nos. 8,221,773; 7,884,185; 8,426,559; 7,858,585; and 8,834,926, incorporated herein by reference in their entireties for all purposes. For example, the selfassembling peptide hydrogels may be or comprise a fragment of any of SEQ ID NOS: 1-20 from U.S. Patent Nos. 8,221,773, 7,884,185, and 7,858,585; and SEQ ID NOS: 1-33 from U.S. Patent No. 8.834,926.

[0109] In some embodiments, the peptides may comprise a fragment of the turn sequence (d)PPT (SEQ ID NO: 109) or V(d)PPTK (SEQ ID NO: 110). One exemplary peptide has a (d)Pro-Pro turn sequence fragment. VKVRVRV(d)PPVRVRKV (SEQ ID NO. 108).

[0110] The peptides may have short sequences between about 2 and about 20 residues, for example, between about 2 and about 16 between about 2 and 14 residues, between about 2 and about 12 residues, or between about 2 and about 10 residues.

[0111] The peptides may have a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern. Exemplary peptides may have a sequence comprising, consisting of, or consisting essentially of [AY]N, [YA]M. Y[AY]N, or A[YA]M, where A is 1-3 amino acids selected from one or more of basic, neutral, aliphatic, aromatic, amphipathic, polar, and charged (e.g., cationic, anionic, or combinations thereof) amino acids, Y is 1-3 hydrophobic amino acids, and N and M are each independently between 1 and 10, for example, between 1 and 8, between 1 and 7, between 1 and 6, or between 1 and 5. In some embodiments, the peptides may have a sequence of Y[AY]N-NH2 or [YA]MY-NH2.

[0112] Any of the charged, hydrophobic, polar, or amphipathic amino acids disclosed herein may derive one or more of their properties from the composition of the preparation, e.g., of the biocompatible solution.Docket No. G2093-7014WO

[0113] Hydrophobic amino acids are those which tend to repel water. Hydrophobic amino acids include alanine, valine, leucine, isoleucine, proline, tyrosine, tryptophan, phenylalanine, methionine, and cysteine. The hydrophobic amino acids may be independently selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, cysteine, and combinations thereof. In some embodiments, the hydrophobic amino acids comprise valine. In some embodiments, the peptide includes at least one valine hydrophobic amino acid.

[0114] Charged amino acids are those which tend to have an electric charge under the given conditions. Charged amino acids may have side chains which form salt bridges. Charged amino acids include alanine, valine, leucine, isoleucine, proline, phenylalanine, cysteine, arginine, lysine, histidine, aspartic acid, and glutamic acid. The peptides may comprise 1-10 charged amino acids, for example 1-8, 1-6, 1-4, or 1-2 charged amino acids.

[0115] The charged amino acids may be positively charged amino acids. The positively charged amino acids may be independently selected from arginine, lysine, histidine, and combinations thereof. The peptides may comprise 1-8. e.g., 1-6, 1-4, or 1-2 arginine residues, lysine residues, or a combination of arginine and lysine residues. In some embodiments, the peptides may comprise 1, 2, 3, or 4 positively charged residues selected from arginine, lysine, or a combination of arginine and lysine.

[0116] The charged amino acids may be negatively charged amino acids. In some embodiments, the negatively charged amino acids may be independently selected from aspartic acid, glutamic acid, and combinations thereof. The peptides may comprise 1-8, e.g., 1-6, 1-4, or 1-2 aspartic acid or glutamic acid resides, or a combination of aspartic acid and glutamic acid residues. In some embodiments, the peptides may comprise 1, 2, 3, or 4 negatively charged residues selected from aspartic acid and glutamic acid or a combination of aspartic acid and glutamic acid.

[0117] Polar amino acids are those which have an uneven charge distribution. Polar amino acids may tend to form hydrogen bonds as proton donors or acceptors. Polar amino acids include glutamine, asparagine, histidine, serine, threonine, tyrosine, and cysteine. In certain embodiments, the peptides may comprise uncharged polar amino acid residues.

[0118] Amphipathic amino acids are those which have both a polar and non-polar component. Amphipathic amino acids may be found at the surface of proteins or lipid membranes.

[0119] Amphipathic amino acids include tryptophan, tyrosine, and methionine.Docket No. G2093-7014WO

[0120] In some embodiments, the peptides may have a turn sequence. Peptides having a turn sequence may have a sequence comprising [AY]N[T], [T][YA]M, Y[AY]N[T], or [T][YA]MY, wherein T is 2-8 turn sequence amino acids.

[0121] The turn sequence amino acids may be selected from proline, for example D-proline and / or L-proline, aspartic acid, and asparagine. In some embodiments, the turn sequence may be (d)PP, (d)PG, or NG, where (d) denotes the D-amino acid. In some embodiments, the turn sequence may comprise a tripeptide sequence (-(d)PPT-) (SEQ ID NO. 109), optionally flanked by charged and / or hydrophobic amino acid residues, such as valine and lysine, (-V(d)PPTK-) (SEQ ID NO: 110).

[0122] In some embodiments, the peptides may be substantially free of a turn sequence. Peptides that are substantially free of a turn sequence may be free of all turn sequence amino acids or may comprise turn sequence amino acids which are not configured or positioned to provide a folding motif, specifically a hairpin bend folding motif. In some embodiments, the peptides may be free of one or more of proline, e.g., free of D-proline or L-proline, aspartic acid, and / or asparagine. In other embodiments, the peptides may comprise one or more of proline, aspartic acid, and / or asparagine, but be substantially free or free of a turn sequence.

[0123] In some embodiments, at least a fraction of the peptides in the preparation may comprise a turn sequence and / or at least a fraction of the peptides in the preparation may be substantially free of a turn sequence. For instance, in some embodiments, at least 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the peptides may be substantially free of a turn sequence. In other embodiments, the preparation may be free of peptides comprising a turn sequence.

[0124] The inventors also surprisingly discovered that the short peptides disclosed herein, for example, peptides having less than 8, less than 6, or even less than 4 charged amino acid residues, exhibit antimicrobial properties. The short peptides disclosed herein were also found to be cytocompatible. While not wishing to be bound by theory, it is believed that the shorter peptides are capable of penetrating skin more efficiently than longer peptide sequences, for example, than peptide sequences having more than 12, more than 16, or more than 20 amino acid residues. Additionally, it is believed that the peptides lacking a turn sequence may be more cytocompatible and / or capable of penetrating skin more efficiently than peptides having a turn sequence. Finally, it is believed that peptides having at least one negatively charged amino acidDocket No. G2093-7014WO

[0125] residue, such as glutamic acid, may be more cytocompatible and / or exhibit superior mechanical properties than peptides lacking a negatively charged amino acid residue.

[0126] The desired properties of the peptides may be controlled by peptide design. Any of the amino acid residues may be a D isoform. Any of the amino acid residues may be an L isoform.

[0127] In certain embodiments, the peptides may include additional amino acids, for example, an epitope. For example, the peptides may include additional functional groups, optionally selected by peptide design. Exemplary functional groups disclosed herein comprise a biologically derived motif or bioactive functional group, for example, having an effect on biological processes such as cell signal transduction, cell adhesion in the extra-cellular matrix (ECM), cell growth, and cell mobility.

[0128] Exemplary bioactive functional groups include laminin, bone marrow homing, collagen (e.g., I, II, and VI), bone marrow purification, and RGD / fibronectin types, VEGF, Substance P, Thymosin Beta, Cardiac Homing Peptide, Bone Marrow Homing Peptide, Osteopontin, and Ostegenic peptide. Other exemplary bioactive functional groups are disclosed in U.S. Patent Application Publication No. 2024 / 0366717, titled “Antimicrobial matrix formed from peptide hydrogels,” which is incorporated herein by reference in its entirety for all purposes.

[0129] The peptide may be a fusion peptide. For example, the peptide may include a functional group. The functional group may be engineered for a target indication, e.g., tissue engineering of a target tissue. The target indication may include, for example, cell culture, cell delivery, wound healing, and / or cosmetic or therapeutic treatment or effect, e.g., to provide antioxidant properties, collagen-stimulation, cell adhesion, etc. One exemplary functional group is KTTKS, which provides collagen stimulation. Integration of KTTKS into a peptide sequence may provide sustained delivery or improved skin retention of the peptide, an unexpected improvement over use of the peptide alone. Thus, the peptide may be engineered by design to self-assemble into a hydrogel which is substantially biocompatible. Exemplary functional groups include RGD, IKVAV, YIGSR, LKKTETQ, SNKPGVL, PKPQQFFGLM, GKLTWQELYQLKYKGI, GGG, and KTTKS (SEQ ID NOS: 98-106, respectively).

[0130] In some embodiments, the peptide may include a modification selected from a linker and a spacer. Peptide “linkers” may generally refer to short amino acid sequences included to link multiple domains of the peptide. Peptide “spacers” may generally refer to amino acid sequences positioned to link and control the spatial relationship of the multiple domains of the assembledDocket No. G2093-7014WO

[0131] protein. The linker or spacer may be hydrophobic or hydrophilic. The linker or spacer may be rigid or flexible. Exemplary spacers include aminohexanoic acid (Ahx) (hydrophobic) and poly (ethylene) glycol (PEG) (hydrophilic). Glycine rich spacers are generally flexible.

[0132] In certain embodiments, the peptides may be terminally modified. The peptide may include one or more terminal modification. The terminal modification may be an N-terminal or C-terminal modification. Exemplary terminal modifications include acetylation, amidation, free carboxyl, PEGylation, lipidation, glycosylation, cyclization, and combinations thereof. In some embodiments, the peptides may have a free amine at the N-terminus, a free carboxyl group at the C-terminus, or both.

[0133] One exemplary terminally modified peptide is N-terminally acetylated Ac-VKVRVRVRVEV-NH2 (SEQ ID NO: 73). The free amine version of the exemplary peptide is H2N-VKVRVRVRVEV-NH2 (SEQ ID NO: 73). Another exemplary free amine peptide is H2N-VKVRVRVRVKV-NH2 (SEQ ID NO: 107). Any of the peptides described herein may be terminally modified or comprise a free amine at the N-terminus. a free carboxyl group at the C-terminus, or both.

[0134] Acetylation is believed to provide improved penetration and / or bioavailability. One exemplary peptide having an acetylated N-terminus is AC-YRRYKRYRRY-NH2 (SEQ ID NO: 42). PEGylation is believed to increase half-life and solubility. One exemplary peptide having PEGylation is PEG-YRRYRKRKYR (SEQ ID NO: 43). Lipidation is believed to improve skin absorption and cellular update. One exemplary peptide having lipidation is Palmityl-YRYRYRKRKR (SEQ ID NO: 44). Cyclization is believed to enhance delivery, peptide stability and self-assembly, sustained and / or enhanced bioactivity, reinforce ECM mimicry, and / or balance charge distribution. One exemplary peptide having cyclization and acetylation is Ac-Cyclo(YRYRYRYRYR)-NH2 (SEQ ID NO. 45). Other exemplary peptides having cyclic conformation are listed in Table 1.

[0135] Table 1: Peptides with Cyclization

[0136] Sequence Effect

[0137] Cyclo(YRRYKRYRRY) Cyclic conformation enhances peptide stability and self-assembly (SEQ ID NO: 42)

[0138] Cyclo(KRRYRYRYRK) Cyclic variant optimized for sustained bioactivity

[0139]

[0140] Docket No. G2093-7014WO

[0141] (SEQ ID NO: 46)

[0142] Cyclo(YRYRYRYRYR) Tyrosine-based cyclic structure reinforces ECM mimicry

[0143] (SEQ ID NO: 45)

[0144] Cyclo(YRKRKRYRYR) Balanced charge distribution for optimal cell interaction

[0145] (SEQ ID NO: 47)

[0146] Cyclo(KYRYRYRKRK) Hydrophobic-cationic balance supports enhanced bioavailability (SEQ ID NO: 24)

[0147]

[0148] In certain embodiments, the peptides may have a sequence comprising, consisting of, or consisting essentially of (Xi X2 X3 ... Xn), where n is 2-20, for example, 2-18, 2-16, 2-14, 2-12, or 2-10. The peptide may have alternating hydrophilic and hydrophobic amino acid residues. In some embodiments, the hydrophilic residues may be charged, e.g., cationic. The amino acid residues may be selected from the following:

[0149] Xi is selected from K, R, F, Y, W, P, L, A, M, I, E.

[0150] X2is selected from K, R, Q, T, S, N, G, E.

[0151] X3is selected from R. K, W, Y, P. L, A, M, I.

[0152] X4 is selected from R, K, Q, G, D, E, P.

[0153] X5is selected from R, K, F, Y, W, M, N, A, I.

[0154] X6is selected from R, K, G, S, H, Q, T, P, E.

[0155] X7is selected from R, K, W, Y, P, L, F, A, I.

[0156] Xs is selected from E, D, Q, T, S, G, P.

[0157] X9is selected from R, K, L, F, Y, W, A, I.

[0158] X10 is selected from R, K, T, Q, G, N, P, E.

[0159] Xnis selected from amide (-NH2), free carboxyl (-COOH), acetyl (-COCEE), or other terminal modification, such as PEGylation, lipidation, glycosylation, or other derivatization capable of providing enhanced stability, bioavailability, and / or controlled release.

[0160] Exemplary peptides are listed in Table 2.

[0161] Table 2: Peptide Sequences

[0162] Sequence Effect

[0163] VKRKRKRKEK Cationic balance enhances cellular adhesion and bioactivity.

[0164]

[0165] Docket No. G2093-7014WO

[0166] (SEQ ID NO: 1)

[0167] KRYRYRYRYR Tyrosine-rich for enhanced structural stability and antioxidant (SEQ ID NO: 2) properties.

[0168] YRKRKRYRRY Optimized for membrane interaction and regenerative potential. (SEQ ID NO: 3)

[0169] WRYRYRYRKR Tryptophan increases self-assembly through TT-TT stacking.

[0170] (SEQ ID NO: 4)

[0171] FRKRKRKRKY Phenylalanine stabilizes hydrophobic interactions in self-assembly. (SEQ ID NO: 5)

[0172] YRKRKRKRKY Balanced hydrophilic-hydrophobic interactions for biocompatibility. (SEQ ID NO: 6)

[0173] KYRRYRKRKY Supports structural conformation for enhanced cell signaling.

[0174] (SEQ ID NO: 7)

[0175] WRYRKRKRYK Tryptophan addition for stability in physiological environments. (SEQ ID NO: 8)

[0176] FYRRYKRYRRY Stronger 7t-stacking to promote hydrophobic interactions.

[0177] (SEQ ID NO: 9)

[0178] MYRRYKRYRRY Methionine for oxidative resistance in biological settings.

[0179] (SEQ ID NO: 10)

[0180] RFRKRKRKRKY Reinforced self-assembly and antimicrobial potential.

[0181] (SEQ ID NO: 11)

[0182] YRKRKRKRKF Structural reinforcement for prolonged self-assembly stability.

[0183] (SEQ ID NO: 12)

[0184] KRYRYRKRKF Hydrophilic-hydrophobic tuning for increased penetration.

[0185] (SEQ ID NO: 13)

[0186] YRKRKRKRKQ Glutamine promotes hydration and ECM mimicry.

[0187] (SEQ ID NO: 14)

[0188] YRKRKRYRKF Optimized for tissue integration and cellular migration.

[0189] (SEQ ID NO: 15)

[0190] RWRKRKRYRK Aromatic stacking promotes molecular interaction.

[0191]

[0192] Docket No. G2093-7014WO

[0193] (SEQ ID NO: 16)

[0194] KFRKRKRKRY Increased P-sheet stacking for prolonged bioactivity.

[0195] (SEQ ID NO: 17)

[0196] RYRYRKRKRY Hydrophobicity tuning for deeper tissue penetration.

[0197] (SEQ ID NO: 18)

[0198] RYRKRYRKRK Enhanced molecular flexibility while maintaining self-assembly. (SEQ ID NO: 19)

[0199] YRKRKRKRYK Tuned for regenerative and structural biocompatibility.

[0200] (SEQ ID NO: 20)

[0201] KRYRYRKRYR Alternating charges for improved cellular response.

[0202] (SEQ ID NO: 21)

[0203] RYRYKRKRYR Surface charge interactions optimized for adhesion.

[0204] (SEQ ID NO: 22)

[0205] KRYRYRKRKR Extended hydrophilic-hydrophobic sequence for self-assembly.

[0206] (SEQ ID NO: 23)

[0207] KYRYRYRKRK Structured for integration into extracellular matrices.

[0208] (SEQ ID NO: 24)

[0209] RYRYRKRKRY Designed for skin interaction and hydration support.

[0210] (SEQ ID NO: 25)

[0211] WYRRYKRYRRY Tryptophan enhances membrane interaction and bioactivity.

[0212] (SEQ ID NO: 26)

[0213] FYRRYKRYRRY Phenylalanine stabilizes self-assembly through hydrophobic (SEQ ID NO: 27) interactions.

[0214] MYRRYKRYRRY Methionine substitution improves antioxidant properties.

[0215] (SEQ ID NO: 28)

[0216] IKRKRKRKEK Isoleucine improves hydrophobic packing while lysine maintains (SEQ ID NO: 29) charge balance.

[0217] IERKRKRKEK Glutamic acid modulates pH responsiveness and enhances self(SEQ ID NO: 30) assembly.

[0218] IKIKRKRKRK Alternating isoleucine and lysine strengthens structural rigidity.

[0219]

[0220] Docket No. G2093-7014WO

[0221] (SEQ ID NO: 31)

[0222] EKRKRKRKEK Balanced hydrophobicity and charge interactions for controlled self(SEQ ID NO: 32) assembly.

[0223] IKRYRYRYRYR Isoleucine enhances 0- sheet formation and stabilizes peptide (SEQ ID NO: 33) architecture.

[0224] EYRKRKRYRRY Glutamic acid improves peptide solubility and interaction with (SEQ ID NO: 34) cellular membranes.

[0225] KRKIKIKRKEK Isoleucine repeats reinforce peptide stacking while lysine enhances (SEQ ID NO: 35) bioactivity.

[0226] KRYEYEYRYR Glutamic acid-rich sequences tune electrostatic interactions for self(SEQ ID NO: 36) assembly.

[0227] IKYRYRYRYRK Optimized amphiphilic balance for surface adherence.

[0228] (SEQ ID NO: 37)

[0229] EYRKRKRKEK Glutamic acid further refines pH sensitivity and molecular stability. (SEQ ID NO: 38)

[0230] IEIKRKRKEK Combination of isoleucine and glutamic acid modulates amphiphilic (SEQ ID NO: 39) self-assembly properties.

[0231] IEIKYRYRKRK Balanced charge and hydrophobicity for stable fibril formation.

[0232] (SEQ ID NO: 40)

[0233] IEIKIKIKRKEK Extended isoleucine and glutamic acid network stabilizing peptide (SEQ ID NO: 41) self-assembly.

[0234] VKVRVRVRVEV Contains a glutamic acid residue at the 10thposition.

[0235] (SEQ ID NO. 73)

[0236] VKVRVRVRVKV Similar to SEQ ID NO: 73, except that it contains no glutamic acid (SEQ ID NO: 107) residue.

[0237]

[0238] Peptide Formulations

[0239] The preparation may comprise peptides in a cosmetically acceptable carrier. One cosmetically acceptable carrier is a biocompatible solution. The biocompatible solution of the preparation may refer to a substantially liquid carrier for the peptide. The biocompatible solution may generally be an aqueous solution. The biocompatible solution may comprise water, forDocket No. G2093-7014WO

[0240] example, deionized water. Deionized water may have a resistivity of greater than about 18 MQ and a conductivity of less than about 0.056 pS at 25 °C. Deionized water may have a maximum endotoxin specification of 0.03 endotoxin units (EU) / ml and 1 CFU / mL microbial action or less. Deionized water may have a total organic carbon (TOC) concentration of 10 ppb or less. The biocompatible solution may comprise pharmaceutical grade water. Pharmaceutical grade water may have 500 ppb total organic carbon (TOC) or less and 100 CFU / ml microbial action or less. The biocompatible solution may comprise injection grade water. Injection grade water may have a maximum endotoxin specification of 0.25 endotoxin units (EU) / ml and 10 CFU / 10 ml microbial action or less. In certain embodiments, the preparation or biocompatible solution may be substantially free of chloride ions.

[0241] Exemplary preparations may comprise between about 0.01% w / v and about 10.0% w / v of the peptides, for example, between about 0.15% w / v and about 10.0% w / v of the peptides, between about 0.1% w / v and about 8.0% w / v of the peptide, between about 0.25% w / v and about 6.0% w / v of the peptides, between about 0.5% w / v and about 6.0% w / v of the peptides.

[0242] In certain embodiments, the preparation may comprise less than about 3.0% w / v of the peptides, for example, between about 0.01% w / v and about 0.1% w / v of the peptides, between about 0.1% w / v and about 0.25% w / v of the peptides, between about 0.25% w / v and about 3.0% w / v of the peptides, between about 0.25% w / v and about 2.0% w / v of the peptides, between about 0.25% w / v and about 1.25% w / v of the peptides, between about 0.25% w / v and about 0.5% w / v, between about 0.25% w / v and about 0.75% w / v, between about 0.5% w / v and about 1.5% w / v, between about 0.7% w / v and about 2.0% w / v of the peptides, or between about 0.7% w / v and about 0.8% w / v of the peptides. For instance, the preparation may comprise about 0.01% w / v, about 0.1% w / v, about 0.25% w / v, about 0.5% w / v, about 0.7% w / v, about 0.75% w / v, about 0.8% w / v, about 1.0% w / v, about 1.5% w / v of the peptides, about 2.0% w / v, or about 3.0% w / v.

[0243] In certain embodiments, the preparation may comprise less than about 1.5% w / v of the peptides. The preparation may comprise less than about 1.25% w / v of the peptides, less than about 1.0% w / v of the peptides, less than about 0.75% w / v of the peptides, less than about 0.5% w / v of the peptides, or less than 0.25% w / v of the peptides. In one exemplary embodiment, the preparation may comprise about 0.75% w / v of the peptides. In another exemplary embodiment, the preparation may comprise about 0.25% w / v of the peptides.Docket No. G2093-7014WO

[0244] In some embodiments, the preparation may comprise a buffer. The “buffer” may refer to an agent configured to induce gelation, prior to, subsequently to, or concurrently with administration of the preparation to the subject. For example, the preparation may comprise or be combined with up to about 1000 mM of the buffer. The buffer may comprise an effective amount of ionic salts and a buffering agent, for example, to induce gelation and / or provide desired properties. For example, the buffer may be formulated to control or maintain pH of the preparation.

[0245] In particular embodiments, the buffer may have an effective amount of ionic salts to control stiffness of the hydrogel. The “ionic salt” may refer to a compound which dissociates into ions in solution. The buffer may comprise between about 3 mM and 400 mM ionic salts. For example, the buffer may comprise between about 3 mM and 200 mM ionic salts, between about 3 mM and about 10 mM, between about 10 mM and about 50 mM, between about 50 mM and about 100 mM, between about 100 mM and about 200 mM, or between about 200 mM and about 400 mM ionic salts. The ionic salt may be one that dissociates into at least one of sodium, potassium, calcium, magnesium, iron, ammonium, pyridium, quaternary ammonium, chloride, citrate, acetate, and sulfate ions. The ionic salts may comprise sodium chloride, ammonium chloride, magnesium chloride, potassium chloride, calcium chloride, ammonium sulfate, magnesium sulfate, sodium sulfate, potassium sulfate, calcium sulfate, sodium bicarbonate, and combinations thereof.

[0246] In exemplary embodiments, the buffer may comprise between about 1 mM and about 200 mM sodium chloride. For example, the buffer may comprise between about 1 mM and about 3 mM, between about 3 mM and about 5 mM, between about 5 mM and about 10 mM, between about 10 mM and about 50 mM, between about 50 mM and about 100 mM, between about 100 mM and about 150 mM. or between about 150 mM and about 200 mM sodium chloride The buffer may comprise from about 1 mM to about 150 mM of a biological buffering agent. For example, the buffer may comprise from about ImM to about 3 mM, from about 3 mM to about 5 mM, from about 5 mM to about 10 mM, from about 10 mM to about 20 mM, from about 20 mM to about 50 mM, from about 50 mM to about 100 mM, or from about 100 mM to about 150 mM of a biological buffering agent. The biological buffering agent may be selected from Bis-tris propane (BTP), 4-(2-hydroxyethyl)-l -piperazineethanesulfonic acid (HEPES), Dulbecco's Modified Eagle Medium (DMEM), tris(hydroxymethyl)aminomethane (TRIS), 2-(N-Docket No. G2093-7014WO

[0247] Morpholino)ethanesulfonic acid hemisodium salt, 4-Morpholineethanesulfonic acid hemisodium salt (MES), 3-(N morpholino)propanesulfonic acid (MOPS), and 3-(N-morpholino)propanesulfonic acid (MOBS), Tricine, Bicine, (tris(hydroxymethyl)methylamino)propanesulfonic acid (TAPS), N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), P-Hydroxy-4-morpholinepropanesulfonic acid, 3-Morpholino-2-hydroxypropanesulfonic acid (MOPSO), (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) (BES) and combinations thereof. Other biological buffering agents are within the scope of the disclosure.

[0248] In exemplary embodiments, the buffer may comprise from about 1 mM to about 150 mM of BTP. The buffer may comprise from about ImM to about 3 mM, from about 3 mM to about 5 mM, from about 5 mM to about 10 mM, from about 10 mM to about 20 mM, from about 20 mM to about 50 mM, from about 50 mM to about 100 mM, or from about 100 mM to about 150 mM BTP.

[0249] In certain embodiments, the peptide preparation and buffer may be combined to form a hydrogel at a ratio of between about 2:1 to 0.5:1 peptide preparation to buffer. In some embodiments, the peptide preparation and buffer may be combined to form the hydrogel at a ratio of about 1:1.

[0250] The peptides may be synthetic, e.g., produced synthetically. Thus, the peptides may provide ease of manufacturing, scale-up. and quality control. In general, the peptides may be manufactured without the use of plant or animal expression systems. The peptides may be substantially free of naturally occurring endotoxins and disease-transmitting pathogens. In addition, the peptide sequence and functional groups may be tuned, allowing a versatility in control and design of the assembled hydrogel, including with respect to physical and chemical properties, such as biodegradation, mechanical properties, and biological activity.

[0251] In some embodiments, for example, if the preparation has been lyophilized or dried, e.g., freeze-dried, the preparation may be in dried form. The preparation may comprise little to no residual moisture. Thus, the preparation may be substantially free of the biocompatible solution.

[0252] The peptides in the preparation may be purified. As disclosed herein, “purified” with respect to the peptides in the preparation, may refer to peptide samples treated for removal of incorrect peptides. Peptide purity may refer to the amount of correct peptide relative to all peptides in a sample. Correct peptides are those peptides which have a sequence matching theDocket No. G2093-7014WO

[0253] desired sequence. Incorrect peptides are those peptides which have at least one synthesis error or failure. Specifically, incorrect peptides may have at least one amino acid moiety which does not match the desired sequence. In some embodiments, the peptides may be at least 50% purified, for example, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or at least 99.9%.

[0254] The preparation may be purified. As disclosed herein, “purified” with respect to the preparation, may refer to compositions treated for removal of contaminants. In particular, the purified preparation may have a composition suitable for clinical application. For example, the preparation may be purified to meet health and / or regulatory standards for clinical administration. The preparation may be at least 80% purified, for example, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or at least 99.9%.

[0255] In certain embodiments, the preparation may be purified to remove or reduce residual organic solvent content from solid phase synthesis of the peptides. The preparation may comprise less than 20% residual organic solvent by weight. The preparation may comprise less than 15% residual organic solvent by weight. The preparation may comprise less than 10% residual organic solvent by weight. For example, the preparation may comprise less than 8%, less than 5%, less than 2%, less than 1%, or less than 0.1% residual organic solvent by weight. Exemplary organic solvents which may be removed or reduced from the synthesized peptide include trifluoroacetic acid (TFA), acetonitrile, isopropanol, N,N-Dimethylformamide, triethylamine, Ethyl Ether, and acetic acid.

[0256] In general, the purified preparation and / or hydrogel may have properties consistent with regulatory limits defined by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).

[0257] The preparation or peptides may comprise counterions. As disclosed herein, a counterion may refer to a charge balancing ion. The preparation or peptide may have an effective amount of counterions to render the preparation substantially electrically neutral. The preparation or peptides may have an effective amount of counterions to render the preparation substantially biocompatible and / or stable. The preparation or peptides may have an effective amount of counterions to control repulsion of anionic or cationic residues of the peptide. The concentration of counterions may be dependent on the peptide sequence and concentration of the peptide and any additives. In exemplary embodiments, the peptide may comprise between 0.1-20%Docket No. G2093-7014WO

[0258] counterions. Additionally, the charge of the counterions may be dependent on the charge of the peptides and any additives. Thus, the counterions may be anions or cations. In general, the counterions may be cytocompatible. In certain embodiments, the counterions may be biocompatible. For instance, the counterions may comprise acetate, citrate, ammonium, fluoride, or chloride. In other embodiments, the preparation or peptide may be substantially free of acetate, citrate, ammonium, fluoride, or chloride counterions. In some embodiments, the peptide is present as a pharmaceutically or cosmetically acceptable salt selected from acetate, chloride, sulfate, phosphate, citrate, or lactate.

[0259] The preparation may have a pH level of between about 3.0 and 8.0. In some embodiments, the preparation may have a substantially physiological pH level of between about 7.0 and 8.0. The preparation may have a pH level of between about 7.3 and 7.5. In other embodiments, the preparation may have a dermatologically compatible pH level of between about 5 and 8.0. The preparation may have a pH level of between about 5 and 7.6, 5.5 and 7.0, 5.0 and 6.5, 5.0 and 5.5. or 5.5 and 6.5, for example, between about 6.3 and 6.5, or about 6.5.

[0260] The preparation comprise at least one of water, an acid, and a base. The acid and / or base may be added in an amount effective to control pH of the preparation to be a substantially physiological pH. In other embodiments, the preparation may be acidic, alkali, or substantially neutral. The preparation may be selected to control pH of the preparation and maintain a desired pH at the target site. Thus, the properties of the preparation may be selected based on the target site. The preparation may have additional properties as selected, for example, net charge, presence or absence of additional proteins, etc. The preparation may additionally comprise one or more minerals.

[0261] The preparation may comprise an effective amount of a cationic or anionic salt. The cationic or anionic salt may be added in an amount effective to control pH of the preparation, for example, to be substantially physiological and / or dermatologically compatible. One exemplary salt is NaCl (e.g., 4.5 to 6, or about 4.5, 5, 5.5, or 6 mM NaCl). In some embodiments, the preparation may comprise an effective amount of a dermatologically compatible buffer, such as an amino acid derived buffer. Exemplary amino acid derived buffers include histidine-based or glycylglycine solutions. In some embodiments, the preparation may comprise an effective amount of a zwitterionic buffer. Exemplary zwitterionic buffers include 2- [4- (2-hydroxyethyl)piperazin-l-yl] ethanesulfonic acid (HEPES) and 3-(N-morpholino)propanesulfonicDocket No. G2093-7014WO

[0262] acid (MOPS). In some embodiments, the preparation may comprise an effective amount of an organic acid and / or salt thereof, e.g., lactobionic acid, lactobionate salt, taurine, taurate salts, and combinations thereof. In some embodiments, the preparation may comprise an effective amount of a chelating buffer, e.g., phytic acid, sodium phytate, or a combination thereof.

[0263] In certain embodiments, the preparation may be formulated for a combination treatment. The preparation may include at least one active agent configured to provide a combination treatment. In some embodiments, the preparation may exhibit synergistic results with combination of the active agent. The active agent may be, for example, an antibacterial composition, an antiviral composition, an antifungal composition, an anti-inflammatory composition, a hemostat, an anti-odor composition, an analgesic, local anesthetic, or a pain-relief composition. The preparation may be formulated for administration in conjunction with one of the aforementioned compositions. The preparation may be formulated for simultaneous or concurrent combination administration. The preparation may be formulated for sequential combination administration.

[0264] In some embodiments, the preparation may be thermally stable between -20 °C and 150 °C, between -20 °C and 125 °C, between -20 °C and 100 °C, between 2 °C and 125 °C, and between 37 °C and 125 °C. As disclosed herein, “thermal stability” refers to the ability to withstand temperature treatment without substantial degradation, loss of self-assembly, loss of biological activity, or loss of chemical activity.

[0265] In some embodiments, the preparation may be stable for at least 6 months, at least 12 months, at least 24 months, or at least 36 months, when stored at 15 to 25°C, with no more than 10% peptide degradation, as determined by HPLC.

[0266] In certain embodiments, the preparation may be sterile or sterilized. For example, the preparation may remain substantially sterile without the addition of a preservative. It was surprisingly discovered that the peptides have the ability to withstand sterilization, e.g., high temperature sterilization, without substantial degradation, loss of self-assembly, loss of biological activity, or loss of chemical activity.

[0267] The preparation may be sterilized by autoclave or steam sterilization. During autoclave or steam sterilization, the preparation may be heated to a temperature of between 120 °C to 150 °C, for example, up to 125 °C, up to 135 °C, or up to 150 °C. The preparation may be held at theDocket No. G2093-7014WO

[0268] autoclave or steam temperature for at least about 2 minutes, for example, between about 2-20 minutes or between about 10-160 minutes.

[0269] In certain embodiments, the preparation may be pasteurized. During pasteurization, the preparation may be heated to a temperature of between 50 °C to 100 °C, for example, up to 60 °C, up to 70 °C, or up to 100 °C. The preparation may be held at pasteurization temperature for at least about 15 seconds, for example, between about 1-30 minutes or between about 3-15 minutes.

[0270] In certain embodiments, the preparation may be sterilized by ultra- high temperature (UHT) or high temperature / short time (HTST) sterilization. During UHT or HTST sterilization, the preparation may be heated to a temperature of between 100 °C to 150 °C, for example, up to 130 °C, up to 140 °C, or up to 150 °C. The preparation may be held at UHT or HTST temperature for at least about 15 seconds, for example, between about less than 1 minute to about 6 minutes, for example, between about 2-4 minutes.

[0271] The autoclave, steam, pasteurization, UHT or HTST sterilization may be sufficient to sterilize at least about 90%, 95%. 99%, 99.9%, 99.99%, or 99.999% of any pathogenic microorganism. The preparation may remain stable during and after sterilization.

[0272] In certain embodiments, the sterilization may be terminal. Terminal sterilization may refer to treatment of the preparation in a sealed end-use package.

[0273] The preparation may have a maximum endotoxin unit (EU) / mg of peptide.

[0274] The preparations may additionally comprise a moisturizing agent, deodorizing agent, fragrance, colorant, insect repellant, cleansing agent, UV-blocking agent, or combinations thereof.

[0275] The preparation may be formulated for immediate release or extended release. The preparation may be formulated for controlled or sustained release. For example, the preparation may be formulated for sustained release over a period of 6 hours, 12 hours, 18 hours, 24 hours, 36 hours. 48 hours, or more.

[0276] Finished Product

[0277] The preparations disclosed herein may be provided as a finished product packaged in an end-use container for distribution to a consumer. For instance, the preparation may be packaged in one or more devices for use and / or delivery of the preparation. The device for use and / orDocket No. G2093-7014WO

[0278] delivery of the preparation may comprise any vessel or vial suitable for distribution of the product to the consumer.

[0279] In certain embodiments, the preparation may be packaged in a delivery device. The delivery device may be a pre-filled packaging, for example, a pre-filled syringe, spray bottle, ampule, or tube. FIG. 4 is a schematic diagram of the preparation packaged in an end-use container. The exemplary end-use container of FIG. 4 is a pre-filled syringe. The end-use container may be employed as a delivery device.

[0280] Exemplary delivery devices include a syringe, catheter, dropper, spray, e.g. in conjunction with a bottle, tube, ampule, film, or impregnated material. The spray device may be, for example, a topical or nasal spray. The type of delivery device may be selected based on a target tissue for administration. Additionally, the properties of the delivery device may be selected based on the target tissue. For instance, a syringe for topical delivery of the preparation may have a larger passage than a syringe for injection of the preparation.

[0281] In some embodiments, the syringe may be used for topical application of the preparation. In other embodiments, the syringe may comprise a needle for parenteral application. The needle of the syringe may have a Birmingham system gauge between 7 and 34. The catheter may be used for parenteral application. The needle of the catheter may have a Birmingham system gauge between 14 and 26. The preparation may be formulated for administration through a particular gauge needle. For instance, the preparation may be selected to have a variable viscosity that will allow application of the preparation through a particular gauge needle.

[0282] In some embodiments, a spray bottle may be used for topical application of the preparation. The spray bottle may comprise a container for the preparation and a spray nozzle. The spray nozzle may be configured for targeted delivery to a target tissue. For instance, a spray nozzle for targeted delivery to an epithelial tissue may have a substantially flat surface and a spray nozzle for targeted delivery to an intranasal tissue may have a substantially conical surface. The spray nozzle may be configured to deliver a predetermined amount of the preparation. In some embodiments, the spray nozzle may be configured to deliver the preparation in substantially unidirectional flow, optionally, regardless of orientation of the spray bottle.

[0283] The spray nozzle may be configured to reduce retrograde flow. In certain embodiments, the spray nozzle may be spring-loaded. In other embodiments, the spray nozzle may be pressure actuated. The actuation pressure may be selected based on the variable viscosity of theDocket No. G2093-7014WO

[0284] preparation. For instance, the actuation pressure may be selected to be sufficient to dispense the preparation through the spray nozzle.

[0285] A film or impregnated material may be used for topical application of the preparation. The film or impregnated material may be saturated with the preparation. The film or impregnated material may be used as a barrier dressing and / or hemostat. In some embodiments, the film or impregnated material may accompany a bander dressing.

[0286] The delivery device may be a single use device. The delivery device may be a multiple use device. In some embodiments, the delivery device may comprise a second chamber for an additional formulation or compound to be administered to the subject. The second chamber may be separated from the first chamber comprising the preparation.

[0287] The delivery device may generally be formed or lined with an inert, thermally- stable material. In certain embodiments, the material may be opaque and / or shatter resistant.

[0288] The finished product may be sterile or sterilized. For example, the finished product may be sterilized using autoclave or steam sterilization, optionally terminal autoclave or steam sterilization.

[0289] Methods of Providing Cosmesis

[0290] The peptides disclosed herein may be administered to provide cosmesis. For instance, the peptides disclosed herein may be administered for cosmetic use or for non-therapeutic improvement of tissue appearance. Certain properties of the peptides have a synergistic effect on cosmesis procedures. For instance, the anti-microbial effect of the peptides may provide protection against pathogenic invaders; the peptides may form a three-dimensional cryoprotective cell matrix locally at the target site; the peptides may reduce inflammation and redness at the target site; substantially alternating hydrophilic and hydrophobic residues may enhance skin and cell penetration; amino acids such as Arg, Lys, Vai, Tyr, Pro, and Glu may provide antimicrobial, immunomodulatory, tissue adhesion, and structural properties. Such properties of the peptides are believed to provide superior treatment associated with cosmetic procedures. As such, administration of the peptides disclosed herein may accelerate healing and / or regeneration of skin.

[0291] The peptides described herein may provide inflammation modulation by reducing redness and irritation. For instance, in certain embodiments, administration of the peptides disclosedDocket No. G2093-7014WO

[0292] herein may reduce inflammation and / or irritation by at least 5%, 10%, 15%, 20%, or 25% within 48 hours from administration. In some embodiments, administration of the peptides disclosed herein may reduce redness by at least 40%, 45%, 50%, 55%. or 60% within 48 hours from administration.

[0293] Thus, in accordance with certain aspects, methods of providing cosmesis are disclosed herein. The methods may comprise administering a preparation comprising one or more peptides. The peptides may be administered in an amount effective to provide a therapeutic and / or cosmetic effect at the target tissue. The method may comprise administering to the subject an effective amount of the preparation to provide cosmesis.

[0294] Providing cosmesis may include, for example, improving skin integrity, improving skin surface topology, reducing or preventing degradation of collagen in the skin of a subject or increasing the collagen content in the skin of a subject, reducing or preventing inflammation in the skin or a hair follicle, preventing, limiting, or inhibiting progression of an appearance or effect of aging in the skin, preventing, limiting, or inhibiting skin inflammation, preventing, limiting, or inhibiting injury to skin integrity or condition, substantially maintaining a state of skin integrity or condition, preventing, limiting, or inhibiting a topographical change of a cutaneous layer of skin, etc. In certain embodiments, cosmesis may include providing anti-aging and / or photoaging treatment or prevention.

[0295] The methods, and any aspects of the foregoing, may further comprise one or more of the steps: i) identifying a subject in need of a cosmesis procedure; and (ii) providing a preparation of the disclosure.

[0296] In any of the foregoing embodiments, and any aspects of the foregoing, when the term “preventing” is used the term may refers to at least a partial inhibition, for example a 10% inhibition, a 20% inhibition, a 30% inhibition, a 40% inhibition, 50% inhibition, a 60% inhibition, a 70% inhibition, an 80% inhibition, a 90% inhibition, a 95% inhibition or greater than 95% inhibition.

[0297] In certain embodiments, the methods may comprise treating or preventing skin wrinkles. In certain aspects of this embodiment, the administration decreases wrinkle length, decreases wrinkle depth, decreases the number of wrinkles in a defined area, decreases the spacing between wrinkles, or a combination of the foregoing.Docket No. G2093-7014WO

[0298] In some aspects, at least one wrinkle treated in the subject may comprise a fine line, surface line, or deep furrow. An amount and / or a frequency of administration may be sufficient to decrease an appearance, e.g.. severity, of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a width of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a length of wrinkle in the subject. An amount and / or a frequency of administration may be sufficient to decrease a depth of wrinkle in the subject.

[0299] An amount and / or a frequency of administration may be sufficient to treat, inhibit, or prevent the progression of at least one of scarring (e.g., scar relating to sunburn, bed sore, wound, inflammatory lesion, or burn), skin thickening (e.g. keloid scarring), crack, fissure, heloma, sebum secretion, skin thickening, wrinkle, sun spot, skin tag, dark patch, stretch mark, spider vein, varicose vein, age spot, or pore appearance in the subject. An amount and / or a frequency of administration may be sufficient to reduce, inhibit, or prevent the progression of blotchiness or discoloration (e.g.. vitiligo or post-inflammatory hyperpigmentation) associated with skin of the subject. An amount and / or a frequency of administration may be sufficient to reduce, inhibit, or prevent the progression of freckles associated with skin of the subject. An amount and / or a frequency of administration may be sufficient to improve skin barrier function, promote firmness, hydration, elasticity, radiance, tone evenness, visual smoothness, or tactile smoothness associated with skin of the subject. An amount and / or frequency of administration may be sufficient to treat or manage skin microbiome dysbiosis and / or microbial colonization of skin. An amount and / or frequency of administration may be sufficient to manage acne, e.g., inflammatory or non-inflammatoiy acne lesions, post-acne sequelae, or post-procedure microbial colonization of skin, including acne-causing pathogenic microorganisms.

[0300] In certain embodiments, the peptides disclosed herein may provide reduction of cutaneous colonization by Pseudomonas aeruginosa and / or methicillin-resistant Staphylococcus aureus by at least 4 log 10 CFU within 24 hours of topical application.

[0301] An amount and / or frequency of administration may be sufficient to modify or reduce a score of a parameter on the Griffiths’ 10-point scale, for example, as graded by the subject or a clinical grader, according to the following medical definitions (with half-point scores assigned as necessary to accurately describe the skin condition):

[0302] 0 = none (best possible condition)Docket No. G2093-7014WO

[0303] I to 3 = mild

[0304] 4 to 6 = moderate

[0305] 7 to 9 = severe (worst possible condition).

[0306] Exemplary parameters include oily appearance (shine and feel) with 0 = no shine, flat / matte appearance and 9 = strong shiny / oily appearance; pore appearance with 0 = small, tight, barely perceptible pores and 9 = large, noticeable pores; radiance with 0 = radiant, luminous appearance and 9 = dull / matte and or sallow appearance; blotchiness with 0 = no blotchines s / clear and 9 = blotchy skin appearance; skin tone (color) evenness with 0 = even, healthy skin color and 9 = uneven, discolored appearance; visual smoothness with 0 = smooth, even looking skin texture and 9 = rough, uneven looking skin texture; and tactile smoothness with 0 = smooth, even feeling skin texture and 9 = rough, uneven feeling skin texture. The modification or reduction of score may be by 9 points, 8 points, 7 points, 6 points, 5 points, 4 points, 3 points, 2 points, or 1 point.

[0307] In some aspects, administering an effective amount of the peptides may limit or inhibit injury to skin integrity of a cutaneous layer of skin in the subject. Administering an effective amount of the peptides may prevent an undesired topographical change of the cutaneous layer of skin in the subject. Administering an effective amount of the peptides may slow progression from a first topographical, structural, or matrix profile to a second topographical, structural, or matrix profile associated with the cutaneous layer of skin in the subject. In some aspects, the cutaneous layer may pertain to an epidermis (e.g. stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, or stratum basalis), a basement membrane, a dermal-epidermal junction, a dermis (e.g. papillary dermis, reticular dermis, or any vasculature comprising the dermis), or subcutis (e.g. subcutaneous fat layer) of the subject.

[0308] In some aspects, administering an effective amount of the peptides may treat or prevent a change in skin pigmentation. Treating or preventing a change in skin pigmentation may include treating, preventing, limiting, or inhibiting a change in melanocyte function. The change in melanocyte function may be associated with one or more of vitiligo, senile lentigines, mottled pigmentation, reticular pigmentation, punctate pigmentation, ectopic pigmentation, perifollicular pigmentation, interfollicular pigmentation, hypopigmentation or hyperpigmentation (e.g., patchy, focal, or diffuse hypopigmentation or hyperpigmentation), erythema, scaling, and telangiectasia. The change in skin pigmentation and / or melanocyte function may be local or systemic.Docket No. G2093-7014WO

[0309] Treating or preventing a change in skin pigmentation may include treating, preventing, limiting, or inhibiting a change in dermal pigmentation and / or epidermal pigmentation (e.g., basal and / or suprabasal pigmentation). In certain embodiments, the change may comprise formation of localized high and low pigmentation in a dermal layer. In some embodiments, the change may comprise increased pigmentation in an epidermal layer. The change in skin pigmentation may be associated with hyperplasia, acanthosis, hyperkeratosis, parakeratosis, orthokeratosis, hypomelanosis, melanogenesis, and / or increase epidermal thickness.

[0310] In some aspects, the skin of the subject may be substantially non-diseased. The skin of the subject may be substantially uninjured. The skin of the subject may be substantially free of inflammatory lesions. The skin of the subject may be substantially free of a mild to severe crack, fissure, or wrinkle. The skin of the subject may be substantially free of a mild to severe scar (e.g., scar relating to sunburn, bed sore, wound, inflammatory lesion, or burn) or stretch mark. The skin of the subject may be substantially free of a mild to severe sun spot, dark patch, or age spot. The skin of the subject may be substantially free of a mild to severe heloma, skin thickening, skin tag, or keloid scar. The skin of the subject may be substantially free of an appearance of a varicose vein or a spider vein. The skin of the subject may be substantially free of a mild to severe appearance of pores. The skin of the subject may be substantially free of mild to severe cellulitis.

[0311] The peptides may be administered to a target tissue. In certain embodiments, the target tissue may be an integumental tissue, for example, a tissue selected from an epidermal, dermal, or hypodermal tissue.

[0312] In some embodiments, the methods may comprise topically administering the peptides to the target tissue. The target tissue may be an epidermal tissue. In other embodiments, the methods may comprise parenterally administering the peptides to the target tissue. The target tissue may be a dermal or hypodermal tissue. The target tissue may be on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.

[0313] The peptides described herein may provide antimicrobial protection by preventing bacterial colonization and biofilm formation. The peptides disclosed herein may provide collagen and / or elastin regeneration or production by stimulating tissue recovery and long-term skin rejuvenation. The peptides disclosed herein may promote tissue recovery. The peptides disclosedDocket No. G2093-7014WO

[0314] herein may provide skin hydration and barrier support by protecting and restoring skin barrier integrity, reducing transepidermal water loss. The peptides described herein may reduce wrinkles and fine lines or reduce the appearance of wrinkles and fine lines and / or provide skin rejuvenation by stimulating collagen and / or elastin regeneration or production. In some embodiments, administration of the peptides disclosed herein may restore at least 15%, 20%, 25%, 30%. 35%. or 40% of normal skin barrier function, as measured by transepidermal water loss, within 48 hours from administration.

[0315] The administered peptides may have anti-inflammatory properties at a localized site of administration. In certain embodiments, the administered peptides may provide systemic antiinflammatory properties.

[0316] The administered peptides may have antimicrobial, antiviral, and / or antifungal properties at a localized site of administration. In certain embodiments, the administered peptides may provide systemic antimicrobial, antiviral, and / or antifungal properties.

[0317] The peptides may be administered in an amount effective to treat or prevent a microbial infection associated with the cosmesis procedure. The preparation may be formulated to provide antimicrobial properties upon administration at a target site. As disclosed herein, “antimicrobial” properties may refer to an effect against a microbial population, e.g., killing or inhibiting one or more microorganism from a microbial population.

[0318] The peptides may be administered in combination with a surgical procedure. The surgical procedure may be a cosmesis procedure or may not be associated with a cosmesis procedure. For instance, in certain embodiments, the peptides may be administered to provide cosmesis to a tissue associated with the surgical procedure, such as prevent or reduce the appearance of scars. In accordance with certain embodiments, the peptides disclosed herein may provide accelerated healing by promoting re-epithelialization and wound closure, reducing recovery time after a surgical procedure. For instance, in certain embodiments, administration of the peptides disclosed herein may accelerate re-epithelization and / or wound closure by at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% within 14 days from administration, as compared to a subject that did not receive administration of the peptides.

[0319] The peptides disclosed herein may be administered in combination with a cosmetic procedure. In certain embodiments, the peptides disclosed herein may be used to enhance recovery and reduce symptoms or side effects of cosmetic procedures that involve skin injury.Docket No. G2093-7014WO

[0320] Exemplary cosmetic procedures include laser resurfacing or dermabrasion procedures, microneedling or dermarolling, chemical peels, radiofrequency (RF) skin tightening, laser treatments, e.g., CO2 laser treatments and others, application of injectables. such as neurotoxins and fillers, cryotherapy, thread lifts, such as non-surgical face lifts, microblading, tattooing and permanent makeup, laser hair removal or intense pulsed light (IPL), tattoo removal procedures, and platelet rich plasma (PRP) injection. In some embodiments, the cosmetic procedure may be a surgical procedure. Exemplary surgical cosmetic procedures include skin tightening and / or fat reduction procedures, such as lifts, e.g., face lifts, arm lifts, lower body lifts, thigh lifts, etc., tummy tucks (abdominoplasty), panniculectomy, liposuction, hair transplant procedures, such as implantation of follicles after follicular unit excision (FUE) or follicular unit transplantation (FUT), or other skin graft procedures, which may be in the form of micro grafting, slit grafting, or punch grafting, and others.

[0321] Additionally or alternatively, in certain embodiments, the peptides disclosed herein may provide treatment for hair loss. For example, administration of the peptides may reduce or inhibit hair loss, stimulate or improve hair regrowth, and / or improve or modulate follicular or tissue regeneration. While not wishing to be bound by theory, it is believed that administration of the peptides disclosed provides superior results in supporting hair transplant procedures, for example, by reducing the length of the recovery phase, accelerating healing and / or regeneration of skin, as well as improving follicular and / or tissue regeneration after the procedure.

[0322] The peptides may be administered in an amount effective to treat or prevent a symptom or side effect of the cosmetic procedure. Exemplary symptoms or side effects include redness, swelling, peeling, crust formation, itching, burning, scarring, erythema, edema, contact dermatitis, milia, pain, discomfort, and combinations thereof. In some embodiments, the peptides may be administered in an amount effective to treat or prevent inflammation.

[0323] The peptides may be administered to a subject in need of cosmesis and / or a subject who is planning to undergo a surgical and / or cosmetic procedure. The peptides may be administered to a subject that recently received a surgical and / or cosmetic procedure. The subject may have one or more skin indications commonly treated with cosmesis procedures, such as fine lines and wrinkles, acne, acne scars, hyperpigmentation and / or melasma, age spots and / or sun spots, skin laxity, and / or uneven skin tone or texture. The peptides disclosed herein may be administered to provide post-acne, post-eczema, and / or post-rosacea management.Docket No. G2093-7014WO

[0324] The peptides may be administered in combination with UV-blocking agent, moisturizer, sunscreen, wrinkle cream, retinoid, alpha-hydroxy acid, beta-hydroxy acid, squalene, antioxidant, tretinoin, glycosaminoglycan (GAG), lactic acid, malic acid, citric acid, tartaric acid, hydroquinone, kojic acid, L-ascorbic acid, licorice extract, N-acetyl glucosamine, niacinamide, squalene, soy, dermal filler or injection, e.g. hyaluronic acid or calcium hydroxylapatite, botulinum toxin, laser resurfacing procedure, ultrasound therapy, chemical peel, e.g. glycolic acid peel, trichloroacetic acid or salicylic acid, or dermabrasion procedure.

[0325] The peptides may be administered in combination with an antioxidant. Exemplary antioxidants include CoQlO, vitamin C, vitamin E, carotenoids, e.g., beta-carotene, minerals, e.g., selenium and manganese, glutathione, lipoic acid, flavonoids, betaflavinoids, phenols, polyphenols, phytoestrogens, mitoquinol mesylate, and ubiquinone.

[0326] The peptides may be administered in combination with a biological material. Exemplary biological materials are disclosed in U.S. Patent Application Publication No. 2024 / 0366717 titled “ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS” (incorporated herein by reference in its entirety for all purposes) and include, for example, cells, e.g., multipotent stem cells, pluripotent stem cells, induced pluripotent cells, non-pluripotent cells, mesenchymal stem / stromal cells, bone marrow mononuclear cells, glial cells, progenitor cells, immune cells, specialized cells, terminally differentiated cells, islet cells or cells of the target tissue, cell-derived matter, e.g., secreted material, cell fragments, cell lysates, or other byproducts, secretomes, exosomes, proteins (e.g., signaling proteins), enzymes, serum, plasma, e.g., platelet rich plasma (PRP), spheroids, liposomes, growth factors, cytokines, chemokines, paracrine factors, autocrine factors, genetic material (e.g., RNA or DNA), vesicles, and / or granules, tissue material or tissue-derived material, biological fluids, e.g., natural biological fluids or synthetic biological fluids, or combinations thereof.

[0327] In some embodiments, the peptides disclosed herein may be administered according to a predetermined regimen. The peptides disclosed herein may be administered more than once a day. daily, weekly, monthly, yearly, or bi-yearly. For instance, the peptides may be administered every 6 hours, e.g., every 12 hours, every 24 hours, every 48 hours, or every 72 hours. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more additional doses of the peptides are administered after the initial administration.Docket No. G2093-7014WO

[0328] The peptides disclosed herein may provide immediate release effects. For example, the onset of action of the active ingredient may be less than one minute, several minutes, or less than one hour.

[0329] The peptides disclosed herein may provide delayed release effects. For example, the onset of action of the active ingredient may be more than one hour, several hours, more than one day. more than several days, or more than one week.

[0330] The peptides disclosed herein may provide extended release effects. For example, the peptides may be effective for more than one day, more than several days, more than one week, more than one month, several months, or up to about 6 months.

[0331] The peptides disclosed herein may be administered in combination with an antiinflammatory agent or treatment. Anti-inflammatory agent may refer to a composition or treatment which reduces or inhibits local or systemic inflammation. The anti-inflammatory agent may comprise, e.g., non-steroidal anti-inflammatory drugs (NSAID), antileukotrienes, immune selective anti-inflammatory derivatives (ImSAID), and / or hypothermia treatment.

[0332] The peptides disclosed herein may be administered in combination with an antibacterial, antiviral, and / or antifungal agent. Such agents may refer to compositions or treatments which eliminate or inhibit proliferation of bacterial, viral, and / or fungal organisms, respectively.

[0333] Exemplary antibacterial agents include antibiotics and topical antiseptics and disinfectants. The antiviral agent may be a target- specific antiviral agent or a broad-spectrum antiviral agent (e.g., remdesivir, ritonavir / lopinavir). Exemplary local antiviral agents include topical antiseptics and disinfectants. Exemplary antifungal agents include antifungal antibiotics, synthetic agents (e.g., flucytosine, azoles, allylamines, and echinocandins), and topical antiseptics and disinfectants.

[0334] The peptides disclosed herein may be administered in combination with a treatment or agent to provide anesthesia and / or pain-relief, e.g., local anesthetic. “Anesthetic” may refer to a composition which provides temporary loss of sensation or awareness. The anesthetic may be a general anesthetic (e.g., GABA receptor agonists, NMDA receptor antagonists, or two-pore potassium channel activators) or a local anesthetic (e.g., ester group agents, amide group agents, and naturally derived agents).

[0335] The peptides may be administered in combination with an analgesic or pain-relief agent. “Analgesic” may refer to a composition for systemic treatment or inhibition of pain. The analgesic may comprise an anti-inflammatory agent or an opioid.Docket No. G2093-7014WO

[0336] The peptides disclosed herein may be administered in combination with a hemostat agent. “Hemostat” may refer to a tool or composition to control bleeding. Exemplary hemostat compositions include collagen-based agents, cellulose-based agents, and chitosan-based agents.

[0337] Methods of Administering Peptide Formulations

[0338] The peptide formulations disclosed herein may be administered by any mode of administration known to one of skill in the art. The method of administration may comprise selecting a target site of a subject and administering the preparation to the target site.

[0339] The target site may be any bodily tissue or bloodstream. In some embodiments, the target site may be epithelial tissue, gastrointestinal system tissue, respiratory system tissue, cardiac system tissue, nervous system tissue, reproductive system tissue, ocular tissue, or auditory tissue. The route of administration may be selected based on the target tissue. Exemplary routes of administration are discussed in more detail below.

[0340] In some embodiments, the methods may comprise identifying a subject in need of administration of the preparation. The methods may comprise imaging a target site or monitoring at least one parameter of the subject, systemically or at the target site. Exemplary parameters which may be monitored include temperature, pH, or skin condition (e.g., skin elasticity, redness, dryness, etc.). The response may be recorded, optionally in a memory storing device. In general, any parameter which may inform a user of a need or desire for administration of the preparation may be monitored and / or recorded. The methods may comprise imaging the target site or monitoring at least one parameter of the subject prior to administration of the preparation, concurrently with administration of the preparation, or subsequent to administration of the preparation. For example, the methods may comprise imaging the target site or monitoring at least one parameter of the subject after an initial dose and before a potential subsequent dose of the preparation.

[0341] In certain embodiments, the preparation may be administered responsive to the measured parameter being outside tolerance of a target value. The preparation may be administered automatically or manually in response to the measured parameter.

[0342] The preparation may be formulated for by any mode of administration known to one of skill in the art, such as, topical, parenteral, or enteral administration. The preparation may be formulated for systemic administration.Docket No. G2093-7014WO

[0343] Various pharmaceutically or cosmetically acceptable carriers and their formulations are described in standard formulation treatises, e.g., Remington’s Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2 S, 1988; Aulton, M. and Taylor, K., Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 5th Edition, 2017; Antoine, A., Gupta M.R., and Stagner, W.C., Integrated Pharmaceutics: Applied Preformulation, Product Design, and Regulatory Science, 2013; Dodou K. Exploring the Unconventional Routes - Rectal and Vaginal Dosage Formulations, The Pharmaceutical Journal, 29 Aug. 2012.

[0344] Topical Administration of Peptide Formulations

[0345] In certain embodiments, the peptide formulations may be administered topically. In general, topical administration may include any external or transdermal administration. For instance, the target site for administration may be an epithelial tissue. In particular embodiments, the topical administration may be accompanied by a wound dressing or hemostat.

[0346] The peptides disclosed herein may be formulated in a composition for topical administration. Exemplary topical compositions include aqueous solutions, solid formulations, gels, lotions, ointments, creams, serums, oils and / or salves. The topical compositions disclosed herein may comprise one or more pharmaceutically or cosmetically carrier or excipient.

[0347] The carrier or excipient may be any safe or approved vehicle or diluent for delivery of the active agent, e.g., peptide, to a target tissue. For a topical formulation, the carrier or excipient may be a dermatologically safe or approved vehicle or diluent for delivery of the active agent to skin. The carrier may be selected for delivery of the peptide in a topical formulation, providing stability, biocompatibility, and effective delivery without interfering with the desired biological effects. The carrier and / or excipient may be selected to support or improve stability of the active agent in the formulation, and optionally to provide or improve skin penetration, timed (e.g.. delayed or controlled) delivery, or shelf-stability of the active agent.

[0348] Exemplary earners and excipients include water-based carriers (e.g., water, aloe vera gel, hydrosols (floral waters)), oil-based carriers (e.g., jojoba oil, sweet almond oil, squalane, argan oil, fractionated coconut oil), emulsion systems (e.g. creams, lotions, micellar water), gels or polymers (e.g.. carbomer, xanthan gum, hyaluronic acid gel), solvents (e.g., alcohols (e.g., ethanol, isopropyl alcohol), propylene glycol, glycerin), encapsulation systems (e.g., liposomes,Docket No. G2093-7014WO

[0349] nanoemulsions, microspheres, microcapsules), silicones (e.g., dimethicone, cyclopentasiloxane), powder-based carriers (e.g., silica, starches (e.g., rice, com)), biodegradable or natural carriers (e.g., phospholipids, peptides, polymers (e.g., polylactic acid, polyglycolic acid)).

[0350] In certain embodiments, the preparation may be formulated as an aqueous solution.

[0351] Aqueous solutions may provide uniform application over a larger topical surface. The preparation may comprise the peptides in a biocompatible solution and / or buffer. For example, the peptides may be dissolved or substantially dissolved in the biocompatible solution and / or buffer.

[0352] The aqueous solution may be administered topically with a delivery device. For instance, the preparation may be formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe. In exemplary embodiments, the preparation may be administered topically by syringe. In exemplary embodiments, the preparation may be administered topically by spray. Spray parameters which may be selected for administration include droplet size, spray pattern, capacity, spray impact, spray angle, and spray diameter. Thus, the methods may comprise selecting a spray parameter to correlate with the target site or target indication. For instance, a smaller spray diameter may be selected for administration to a small wound. A specific spray angle may be selected for administration to a target site which is difficult to reach. A denser spray pattern or larger droplet size may be selected for administration to a moist target site. In some embodiments, the spray may be, for example, a nasal spray.

[0353] Exemplary droplet sizes may be between 65 pm to 650 pm. For instance, fine droplets having an average diameter of 65 pm to 225 pm, medium droplets having an average diameter of 225 pm to 400 pm, or coarse droplets having an average diameter of 400 pm to 650 pm may be selected. The spray pattern may range from densely packed droplets to sparse droplets. The spray diameter may range from less than 1 cm to 100 cm. For instance, spray diameter may be selected to be between less than 1 cm and 10 cm, between 10 cm and 50 cm, or between 50 cm and 100 cm. Spray angle may range from 0° to 90°. For instance, spray angle may be selected to be between 0° and 10°, between 10° and 45°, or between 45° and 90°.

[0354] The peptide preparation may be in a substantially solid or gel-like form. For instance, the preparation may be formulated as a powder or gel. Powder preparations may comprise lyophilized peptides. Powder preparations may comprise talcum powder or cornstarch. Gels may comprise or consist of the peptide in a gel form. In certain embodiments, the peptides may self-Docket No. G2093-7014WO

[0355] assemble into a hydrogel. In other embodiments, the gels may further comprise a gelling agent, such as a polymer, e.g., poloxamers, xanthan gum, gellan gum, locust bean gum, and carrageenan.

[0356] The preparation may be in a cream form. For instance, the preparation may be formulated as a cream, ointment, or lotion. The preparation may be formulated as a serum or oil. The preparation may be formulated as a salve. Ointments may comprise anhydrous dispersions of the peptide, e.g., in a mineral oil- white petroleum base. Serums may include oil-based products, gelbased formulas, or lightweight emulsions. Oil-based serums and oils typically include polyphenols, essential fatty acids, and antioxidants. Oil-based serums and oils may be free of preservatives, as they typically lack water. Gel-based serums and water-based serums may contain water, gums, thickeners, and optionally humectants.

[0357] Gel, lotion, ointment, cream, serum, oil and / or salve preparations may comprise a thickener and / or emulsifier. Exemplary thickeners and emulsifiers include emulsifying wax, polysorbate 20, ceteareth 20, cellulose derivatives, guar gum, locust bean gum, xanthan gum, and gelatin. Such preparations may have a viscosity of at least about 1 mPa-s, 10 mPa-s, 100 mPa-s, 1 Pa- s, 5 Pa- s, 10 Pa- s, or 20 Pa- s at room temperature, e.g., between about 20 °C - 25 °C.

[0358] Ointments, lotions, salves, creams, serums, oils, and gels with greater viscosities may provide for a longer residence time than, for example, aqueous solutions. Such formulations may enhance skin penetration and hydration. In certain embodiments, the longer residence time may further allow for a reduced dosing interval. Emulsions may comprise encapsulating agents, such as microspheres, microcapsules, nanoparticles, nanocapsules, micelles, liposomes, niosomes, dendrimers, or cyclodextrin complexes. The encapsulating agents may be used to provide timed or delayed release formulations.

[0359] The topical preparation may include cosmetically acceptable additives, such as one or more preservatives, fillers, bulking agents, fragrances, or colorants. In other embodiments, the preparation may be substantially free of additives. For example, the preparation may be substantially free of preservatives, fillers, bulking agents, fragrances, and / or colorants.

[0360] Exemplary preservatives include phenoxyethanol and ethylhexylglycerin.

[0361] Phenoxyethanol may be present at a concentration of about 0.5% to 1.0% v / v.

[0362] Ethylhexylglycerin may be present at a concentration of about 0.1% to 0.5% v / v.Docket No. G2093-7014WO

[0363] In some embodiments, the preparation may comprise one or more excipients, such as sodium pyrrolidone carboxylate (sodium PC A) at about 0.5% to 2.0% w / v, glycerol at about 1% to 5% v / v, a non-ionic surfactant configured to inhibit lateral bundling of peptide nanofibers, optionally poloxamer 188 at about 0.01% to 0.5% w / v, a biological buffering agent, such as, BisTris Propane buffer at about 1 to 10 mM, and / or NaCl at about 1 to 20 mM. Any of the listed excipients may be combined or omitted from the preparation.

[0364] In some embodiments the preparation may consist or consist essentially of the peptides in an aqueous biocompatible solution. In some embodiments, the preparation may consist or consist essentially of the peptides in a buffer.

[0365] In some embodiments, the preparation may be formulated for topical administration with a film, membrane, or sheet. The film, membrane, or sheet may be a rigid, semi-flexible, or flexible substrate. In certain embodiments, the flexible or semi-flexible substrate may be configured to adopt a topological conformation of the target site. In general, the film, membrane, or sheet may be in the form of a substrate saturated with the preparation. The substrate may be rigid, semi-flexible, or flexible. The film, membrane, or sheet may be administered as a barrier dressing and / or hemostat. The preparation may be administered topically with a film, membrane, or sheet and accompanied by a barrier dressing.

[0366] In certain embodiments, the preparation may be formulated for topical administration as an impregnated material. For instance, the preparation may be formulated for topical administration with a mask or bandage. The mask may be a thin flexible or semi-flexible substrate, such as a fabric, polymer, gel, cellulose, or collagen substrate, impregnated or loaded with the preparation. The mask may provide targeted delivery of the preparation. Exemplary masks include facial sheet masks, under eye masks or patches, spot patches or spot dots (optionally in other shapes, such as stars, triangles, etc.), forehead patches, chin patches, cheek patches, jawline or v-line lifting patches, nose patches or nose strips, neck masks, and / or chest masks. The mask may be self-adhesive or comprise an adhesive. The mask may be designed to be worn for a period of time, for example, 5-30 minutes, 10-20 minutes, or more, and then discarded. Excess preparation may be massaged or patted onto the skin after removal of the mask.

[0367] The bandage may be a flexible substrate, such as fabric (e.g., cotton), polymer, gauze, foam, or paper. The bandage may comprise an area impregnated or loaded with the preparation.Docket No. G2093-7014WO

[0368] The bandage may provide targeted delivery of the preparation. The bandage may comprise an area that is self-adhesive or comprises an adhesive. The bandage may be used as a barrier dressing.

[0369] The peptide formulated as a film, membrane, sheet, barrier dressing, or impregnated material may provide treatment by direct contact with target site. Conventional antimicrobial wound dressings rely on traditional antibiotics and function merely as a vehicle for antibiotic agents. However, the formulations described herein may be designed to provide a biophysical mode of cell-membrane disruption against broad- spectrum (gram-positive and gram-negative) bacterial cultures. Thus, the antimicrobial, antiviral, and / or antifungal peptide film, membrane, sheet, barrier dressing, or impregnated materials may generally avoid concerns around minimum inhibitory bacterial concentrations typical to conventional small molecule loaded polymers. Instead, the peptides disclosed herein may be designed to exert toxicity against gram-positive and gram-negative bacteria (including antibiotic resistant strains) while remaining cell-friendly, non-inflammatory, and non-toxic by selecting amino acid charge ratio of the peptide. Similarly, the peptide disclosed herein may be designed to exert toxicity against fungal organisms (e.g., sporulating and non-sporulating fungal organisms) and / or viral organisms. The film, membrane, sheet, barrier dressing, or impregnated material disclosed herein may provide a temporary extracellular matrix scaffold for tissue regeneration.

[0370] The peptides may be administered topically to any target site in need thereof. Cosmesis treatments are described herein as one exemplary embodiment. However, it should be understood that many other topical target sites and treatments are envisioned, for example, as described herein.

[0371] Parenteral Administration of Peptide Formulations

[0372] In certain embodiments, the peptide formulations may be administered parenterally. In general, parenteral administration may include any route of administration that is not enteral. The preparation may be administered parenterally via a minimally invasive procedure. In particular embodiments, the parenteral administration may include delivery by syringe, e.g., by needle, or catheter. For instance, the parenteral administration may include delivery by injection. The parenteral administration may be intramuscular, subcutaneous, intravenous, or intradermal.Docket No. G2093-7014WO

[0373] The peptide formulations may be administered parenterally to any internal target site in need thereof. For instance, cardiac tissue, nervous tissue, connective tissue, epithelial tissue, or muscular tissue, and others, may be the target site.

[0374] For any of the routes of administration disclosed herein, the methods may comprise administering a single dosage of the preparation. The site of administration may be monitored for a period of time to determine whether a booster or subsequent dosage of the preparation is to be administered. For example, the methods may comprise monitoring the site of administration. A parameter of the subject, optionally at the target site, may be monitored as previously described. The subject may be monitored hourly, every 2-3 hours, every 6-8 hours, every 10-12 hours, every 12-18 hours, or once daily. The subject may be monitored daily, every other day, once every few days, or weekly. The subject may be monitored monthly or bi-monthly. In certain embodiments, the subject may be monitored for a period of up to about 6 months. For example, the subject may be monitored for about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months.

[0375] The methods may comprise administering at least one booster or subsequent dosage of the preparation. For example, the methods may comprise administering a booster dosage to the target site at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days after the first dosage. The methods may comprise administering a booster dosage 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after the first dosage. The methods may comprise administering a booster dosage at least 2 weeks, at least 1 month, at least 6 months, or at least 1 year after the first dosage. In certain embodiments, at least a portion of the peptides may be present at the target site at the time of the booster dosage. In other embodiments, the peptides may be fully metabolized or otherwise eliminated from the target site at the time of the booster dosage.

[0376] EXAMPLES

[0377] The function and advantages of these and other embodiments can be better understood from the following examples. These examples are intended to be illustrative in nature and are not considered to be limiting the scope of the invention.Docket No. G2093-7014WO

[0378] Example 1: Cytotoxicity of Peptide Formulations

[0379] The purpose of this study was to evaluate the cytotoxicity of short peptide formulations (%w / v, 1:1). The test was conducted in Mouse Embryonic Fibroblasts (MEF DI cells) using the CellTiter-Glo® One Solution Luminescence Cell Viability Assay (Promega Corporation, Madison, WI).

[0380] Tables 3-4 contain detailed information about the test and control articles (negative control) used in this study.

[0381] Table 3: Test Articles

[0382] Peptide Sequence

[0383] Compound A Ac-VKVRVRVRVEV-NH2(SEQ ID NO: 73), N-terminally acetylated, acetate counterion, MW 1379.7 (Lot CX- 10-00901 (CPC Scientific))

[0384] Compound B DP10-PTRVRVRVKV-NH2 (SEQ ID NO: 74) (Lot CX- 11-00975

[0385]

[0386] (CPC Scientific))

[0387] Table 4: Test and Control Formulations

[0388] Test Article Description

[0389] 1 Compound A 0.25%, 0.75% and 1.5% w / v

[0390] 2 Compound B 0.25%, 0.75% and 1.5% w / v

[0391] 3 Compound A+B 0.25%, 0.75% and 1.5% w / v

[0392] Control Article Description

[0393] 1 Positive Control 5% DMSO w / v

[0394] 2 Negative Control Complete Media (DMEM+ 10% FBS + 1%

[0395]

[0396] P / S w / v)

[0397] Mouse Fibroblasts MEF DI cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) medium supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin and Streptomycin (P / S) at 37°C in a humid atmosphere with 5% CO2. Upon reaching >70% confluence, MEF DI cells (p=17, 85% viability) were harvested and seeded onto opaque blackwalled 96-well plates at 10,000 cells / well density in 100 pL of complete medium. All experiments were conducted in technical triplicates (three wells per test / control article) and biological duplicates (two independent plates).

[0398] Cells were incubated for 24 hours in complete medium containing 10% FBS and 1% Penicillin and Streptomycin (P / S). The test articles were aliquoted in the biosafety cabinet afterDocket No. G2093-7014WO

[0399] autoclaving and exposed to UV for 15 minutes prior to the treatment. 6 pL of each treatment was pipetted directly into the appropriate wells containing 100 pL of fresh complete media and incubated for 48 hours.

[0400] After incubation, cellular viability was evaluated using the CellTiter-Glo® One Solution Assay (Promega Corporation, Madison, WI), following the manufacturer’s protocol. Plates were first equilibrated at room temperature for approximately 30 minutes. An equal volume of CellTiter-Glo® One Solution was added to each well (100 pL of reagent to 100 pL of existing medium in each well). The plate was placed on an orbital shaker for 2 minutes to mix the contents and induce cell lysis. After which, it was incubated for 10 minutes at room temperature to stabilize the luminescent signal. After incubation, the luminescence was recorded using the BioTek Synergy Hl Multimode Plate Reader (Agilent Technologies, Santa Clara, CA).

[0401] Absorbance readings were normalized to blank wells containing only complete medium and CellTiter-Glo® One Solution.

[0402] Adjusted cell viability percentages (%) were obtained from raw absorbance values after normalizing the negative control (untreated cells). Data is shown as average ± standard deviation (SD) and was compared using One-way ANOVA followed by Dunnet’s multiple comparisons test. The significance level was set at p<0.05.

[0403] The morphological analysis indicated that most of the tested articles were well tolerated by the cells, as summarized in Table 5. A grade 4 reactivity (severe) was found in Compound B and Compound A+B at the concentration 1.5% w / v, while a Grade 1 (Slight) reactivity was found in Compound B and Compound A+B at the concentration 0.75% w / v. All the remaining test articles received a reactivity score Grade 0 (None). Representative pictures of cell morphology for each treatment are shown in FIG. 1.

[0404] FIG. 1 includes images of cellular morphology of MEF DI cells 48 hours after treatment with test and control articles. Healthy cells (NEG) have an elongated, spindle-like shape with numerous cytoplasmatic projections and a prominent nucleus. In contrast, dying cells are often detached, exhibiting a round shape with no cytoplasmic projections. Final magnification: 20x.

[0405] The raw absorbance values and adjusted cell viability rates for CellTiter-Glo® One are shown in Tables 6-9B, plotted in a graph in FIG. 2. FIG. 2 includes a graph showing adjusted cell viability (%) of MEF DI cells incubated with test and control articles for 24 hours with CellTiter-Glo® One Solution. Data are shown as average + standard deviation. ****p<0.0001,Docket No. G2093-7014WO

[0406] ***p=0.0003, **p=0.0076. All other comparisons are not significant. Statistical analysis was performed using one-way ANOVA followed by Dunnet’s multiple comparison test.

[0407] In agreement with the cell morphology and reactivity scores, a significant decrease in cell viability rates was found in the test articles Compound B and Compound A+B at 1.5% w / v (p<0.0001) and the test article Compound B at 0.75% w / v (p=0.0003), although to a lesser extent (<70%). These results indicate that the test article Compound B, alone or in combination with Compound A shows a reduction in cell viability in concentrations equal or higher than 0.75% w / v.

[0408] Table 5: Qualitative morphological grading of cytotoxicity of extracts

[0409] Test / Control Article Grade Reactivity Conditions

[0410] Negative control 0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth

[0411] Positive control 4 Severe Nearly complete or complete destruction of the cell layers

[0412] Compound A 0.25% 0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth Compound A 0.75% 0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth Compound A 1.5% 0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth Compound B 0.25% 0 None Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth Compound B 0.75% 1 Slight No more than 20% of the cells are round,

[0413] loosely attached, slight grow inhibition Compound B 1.5% 4 Severe Nearly complete or complete destruction of the cell layers

[0414] Compound A+B 0 None Discrete intracytoplasmatic granules, no cell 0.25% lysis, no reduction of cell growth Compound A+B 1 Slight No more than 20% of the cells are round, 0.75% loosely attached, slight grow inhibition

[0415]

[0416] Docket No. G2093-7014WO

[0417] Compound A+B 4 Severe Nearly complete or complete destruction of the 1.5% cell layers

[0418]

[0419] Table 6: Raw absorbance values for the CellTiter-Glo® One Solution Assay in MEF DI cells.

[0420] Raw Negative Positive

[0421] Absorbance Control Control

[0422] Plate 1 3377 773

[0423] 3090 921

[0424] 785

[0425] Plate 2 2966 992

[0426] 3303 1128

[0427] 3787 680

[0428] Average 3304.60 879.83

[0429] STD 282.37 150.67

[0430]

[0431] Table 7A: Raw absorbance values for the CellTiter-Glo® One Solution Assay in MEF DI cells treated with test articles: Compound A, Compound B.

[0432] Raw Compound Compound Compound Compound Compound Compound Absorbance A 0.25% A 0.75% A 1.5% B 0.25% B 0.75% B 1.5% Plate 1 4463 3635 4075 3567 3506 1531

[0433] 4104 4536 3374 3417 2748 1250 4716 3458 2576 4555 2488 1404 Plate 2 3508 3392 3538 3544 3006 1491

[0434] 3642 4061 3327 3615 3079 1233 3619 3735 2393 3544 2833 1040 Average 4008.67 3802.83 3213.83 3707.00 2943.33 1324.83 STD 456.94 392.57 571.39 383.93 315.33 169.09

[0435]

[0436] Table 7B: Raw absorbance values for the CellTiter-Glo® One Solution Assay in MEF DI cells treated with test articles: Compound A + B.Docket No. G2093-7014WO

[0437] Raw Absorbance Compound A+B Compound A+B Compound A+B 0.25% 0.75% 1.5%

[0438] Plate 1 2704 2464 1331

[0439] 2755 2053 1384

[0440] 3474 2080 1367

[0441] Plate 2 3299 2500 1280

[0442] 3306 3073 1337

[0443] 3342 2006 1035

[0444] Average 3146.67 2362.67 1289.00

[0445] STD 300.90 373.43 118.16

[0446]

[0447] Table 8: Adjusted cell viability (%) for the CellTiter-Glo® One Solution Assay in MEF DI cells treated with control articles.

[0448] Adjusted Negative Positive

[0449] Viability Control Control

[0450] (%)

[0451] Plate 1 100 23.91

[0452] 100 28.48

[0453] 100 24.28

[0454] Plate 2 100 29.59

[0455] 100 33.65

[0456] 100 20.29

[0457] Average 26.70

[0458] STD 4.37

[0459]

[0460] Table 9A: Adjusted cell viability (%) for the CellTiter-Glo® One Solution Assay in MEF DI cells treated with test articles: Compound A, Compound B.

[0461] Adjusted Compound Compound Compound Compound Compound Compound Viability A 0.25% A 0.75% A 1.5% B 0.25% B 0.75% B 1.5% (%)

[0462] Plate 1 138.02 112.42 126.02 110.31 108.43 47.35

[0463]

[0464] Docket No. G2093-7014WO

[0465] 126.92 140.28 104.35 105.67 84.99 38.66 145.85 106.94 79.67 140.87 76.94 43.42 Plate 2 104.65 101.19 105.55 105.73 89.68 44.48

[0466] 108.65 121.15 99.25 107.85 91.86 36.78 107.97 111.43 71.39 105.73 84.52 31.03 Average 122.01 115.57 97.70 112.69 89.40 40.29 STD 15.95 12.58 17.93 12.71 9.72 5.45

[0467]

[0468] Table 9B: Adjusted cell viability (%) for the CellTiter-Glo® One Solution Assay in MEF DI cells treated with test articles: Compound A + B.

[0469] Adjusted Viability Compound A+B Compound A+B Compound A+B (%) 0.25% 0.75% 1.5%

[0470] Plate 1 83.62 76.20 41.16

[0471] 85.20 63.49 42.80

[0472] 107.44 64.33 42.28

[0473] Plate 2 98.42 74.58 38.19

[0474] 98.63 91.68 39.89

[0475] 99.70 59.84 30.88

[0476] Average 95.50 71.69 39.20

[0477] STD 8.42 10.72 4.02

[0478]

[0479] When compared to the negative control, all tested concentrations of Compound A, as well as 0.25% w / v Compound B and Compound A+B (1:1) were well tolerated and did not impact cell viability. The test articles having 0.75% w / v Compound B and Compound A+B (1:1) exhibited low cytotoxicity with reactivity scores of Grade 1 and 70-90% adjusted cell viability.

[0480] Example 2: Thermostability of Peptide Serum

[0481] Thermostability of a peptide serum containing 0.25% w / v of the peptides of compound A (Example 1) was tested by measuring the composition of the peptide serum (by high performance liquid chromatography (HPLC)) before and after heating to 121 °C for 30 min.Docket No. G2093-7014WO

[0482] FIGS. 3A-3B include chromatograms of the samples before and after heating, respectively. As shown in FIGS. 3A-3B, the peaks are at least 95% similar before and after heating.

[0483] Accordingly, the serum containing compound A is thermostable. The composition will have a long shelf-life at room temperature and can be sterilized by steam sterilization, without significant degradation of the peptide.

[0484] Example 3: Microbial Examination and Antimicrobial Efficacy of Peptide Formulations A study was conducted to evaluate antimicrobial efficacy of the peptide formulations. Tables 10-11 contain detailed information about the test article and reagents used in the study.

[0485] Table 10: Test Article

[0486] Test Article Concentration Sequence

[0487] Compound A 0.25% w / v Ac-VKVRVRVRVEV-NH2(SEQ ID NO: 73) Compound A 0.75% w / v AC-VKVRVRVRVEV-NH2(SEQ ID NO: 73) Compound A 1.5% w / v AC-VKVRVRVRVEV-NH2(SEQ ID NO: 73)

[0488]

[0489] Table 11: Reagents

[0490] Reagent Catalog No. Manufacturer

[0491] Brain Heart Infusion Broth Bl 1000-500.0 Research Products International Corp. Mt.

[0492] Prospect, IL

[0493] Brain Heart Infusion Agar Bl 1500-500.0 Research Products International Corp. Mt.

[0494] Prospect, IL

[0495] Phosphate Buffered Saline SH30256.01 Cytiva, Marlborough, MA

[0496]

[0497] Bacterial stocks were prepared for bioburden testing. The test organisms (Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Escherichia coli, and Candida albicans) were routinely streaked on respective nutrient media (Soybean-Casein Digest Agar (SCDA) or Sabouraud Dextrose Agar (SDA)) and placed in a humidified incubator at 25 °C (fungi) or 35 °C (bacteria) for at least 24-48 hours for colony enumeration. A single, isolated colony was inoculated in nutrient media (Soybean-Casein Digest Broth (SCD) or Sabouraud Dextrose Broth (SD)) and incubated overnight (16-18 hours) at 35 °C with aeration. OvernightDocket No. G2093-7014WO

[0498] cultures were diluted to their target OD600nm and all procedures were performed under a sterile environment. Target OD600nm of the test organisms is listed below in Table 12.

[0499] Bioburden was tested by performing microbial examination of the sterilized test article, Compound A, per USP 61 standards using the test organisms listed above.

[0500] Table 12: Preparation of Test Organisms

[0501] OD600nin Vol. of

[0502] ODfiOOnrn Required Volume of Target diluted undiluted Final Species undiluted Volume Broth ODfiOOnm culture culture ODtfOOnm culture (pL) (pL)

[0503] (1:5) (pL)

[0504] MRSA

[0505] 0.25 1.5 7.5 1200 40.0 1160.0 0.286 (ATCC 33591)

[0506] P. aeruginosa

[0507] 0.25 1.41 7.05 1200 42.6 1157.4 0.28 (ATCC 9027)

[0508] E. coli

[0509] 0.15 1.27 6.35 1200 28.3 1171.7 0.159 (ATCC 25922)

[0510] C. albicans

[0511] 0.25 0.228 1.14 1200 263.2 936.8 0.287 (ATCC 24433)

[0512]

[0513] Bacterial stocks were also prepared for antimicrobial efficacy testing. Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus were routinely streaked on brain heart infusion (BHI) agar and placed in a humidified incubator at 37 °C for at least 18 hours for colony enumeration. A single, isolated colony was inoculated in BHI broth and incubated overnight (16-18 hours) at 37 °C with aeration. Overnight cultures were diluted to a target OD600nm of 0.3, serially diluted, and plated onto BHI agar to determine colony forming units (CFU). All procedures were performed under a sterile environment.

[0514] Methods outlined in ASTM E2315 were modified and used to perform testing. Briefly, to a 1.5mL microcentrifuge tube, 50pL Compound A or BHI broth (bacterial viability control) was added and inoculated with 2.5 L (~106) of diluted culture. All sample tubes were placed in a humidified incubator at 37°C for 24 hours after which all samples were neutralized with lOOpLDocket No. G2093-7014WO

[0515] of BHT and serially diluted to determine colony forming units (CFU). Agar plates were imaged and data recorded.

[0516] A second study was performed using an alternate modified ASTM E2315 to as a validated quantitative assay, which included 24-hour exposure, BHI neutralization, and CFU plate count. The key findings are summarized below:

[0517] Compound A (Ac-VKVRVRVRVEV-NH2(SEQ ID NO. 73) Lot CX- 10-00901) showed complete eradication (6-log reduction) of Pseudomonas aeruginosa (ATCC 9027) and methicillin-resistant Staphylococcus aureus (MRS A, ATCC 33591) at all tested concentrations (0.25%, 0.75%, 1.5% w / v).

[0518] Compound B ((d)PPTRVRVRVKV-NH2(SEQ ID NO. 74) Lot CX- 11-00975) showed complete eradication of P. aeruginosa at all tested concentrations: complete eradication of MRSA at 0.75% and 1.5% w / v; and approximately 1 log reduction at 0.25% w / v MRSA.

[0519] Compound A+B mixture showed complete eradication of both pathogens at 0.25% and 0.75% w / v.

[0520] The results confirm the broad- spectrum antimicrobial efficacy of the short peptides disclosed herein.

[0521] Suitability Test

[0522] Microbial enumeration was performed in accordance with USP 61 standards, ensuring that the inoculated microbial load did not exceed 100 colony-forming units (CFU) per organism. The mean CFU input (FIG. 5A) for each microbial species was as follows: MRSA, 46 CFU; P. aeruginosa, 50 CFU; E. coli, 51 CFU; and C. albicans. 64 CFU. As shown in FIG. 5A, CFU enumeration of prepared cultures of bacteria (A) and fungus (B) for inoculation into samples were within the required range (<100 CFU). Plated cultures were incubated at their respective temperatures.

[0523] Recovery of CFUs from both control and test samples was comparable across all bacterial and fungal strains assessed (FIG. 5B) confirming that the Compound A did not result in growth inhibition / reduction by a factor greater than 2. As shown in FIG. 5B, the suitability testing of Compound A demonstrated no difference in microbial recovery between control and test plates for bacteria (A) and fungus (B). The prepared diluted sample was not inhibiting microbial growth and data is valid. Plated cultures were incubated at their respectiveDocket No. G2093-7014WO

[0524] temperatures for the recommended time and colonies counted at the end of the incubation period. The dashed line in the graphs indicates the maximum limit to achieve a passing result.

[0525] These results indicate that the test method is suitable for the microbial examination of Compound A.

[0526] Bioburden Test

[0527] No microbial growth was observed on the plates inoculated with Compound A or the negative control (PBS) (FIG. 6). As shown in FIG. 6, no growth was observed on uninoculated Soybean-Casein Digest (bacteria) plates (A-B) or Sabouraud Dextrose (fungi) agar plates (C-D) demonstrating that data is valid and none of the tested organisms were detected. The absence of growth on the negative control plates confirms the validity of the experimental results. The absence of growth on the Compound A plates demonstrates that none of the tested organisms were detected in Compound A.

[0528] Bacterial and fungal recovery post-incubation (CFU) are summarized in Tables 13-14 below.

[0529] Table 13: Bacterial Recovery Post-Incubation

[0530] Total number of colonies (CFU)

[0531] Average number Identifier

[0532] of colonies I II MRSA (diluted culture) 48 44 46 P. aeruginosa (diluted culture) 48 52 50 E. coli (diluted culture) 52 50 51 Media + PBS (negative control) 0 0 0 Media + Compound A 0 0 0 Media + MRSA (control) 3 4 3.5 Media + Compound A + MRSA 4 4 4.0 Media + P aeruginosa (control) 4 4 4.0 Media + Compound A + P. aeruginosa 5 3 4.0 Media + E. coli (control) 3 2 2.5 Media + Compound A + E. coli 3 3 3.0

[0533]

[0534] Docket No. G2093-7014WO

[0535] Total number of colonies (CFU)

[0536] Average number Identifier

[0537] of colonies I II

[0538]

[0539] Media used for bacterial preparation: Soybean Casein Digest

[0540] Table 14: Fungal Recovery Post-Incubation

[0541] Total number of colonies (CFU)

[0542] Average number Identifier

[0543] of colonies I II

[0544] C. albicans (diluted culture) 60 68 64 Media + PBS (negative control) 0 0 0 Media + Compound A 0 0 0 Media + C. albicans (control) 3 8 5.5 Media + Compound A + C. albicans 5 7 6

[0545]

[0546] Media used for fungal preparation: Sabouraud Dextrose

[0547] Antimicrobial Efficacy Test

[0548] Compound A was inoculated with an average of 1.04 x 106P. aeruginosa or 1.13 x 106MRSA. For the test articles, prepared cultures were serially diluted 10-fold in PBS and plated onto BHI agar plates for CFU enumeration. For the control tests, prepared cultures of each test organism were added to nutrient broth to confirm inoculum viability. The plates were incubated at 37°C for 18-24 hours. Positive controls confirmed bacterial viability (FIG. 7 and FIG. 8A). As shown in FIGS. 8A-8B, no growth was observed on agar plates, indicating complete eradication 24 hours after incubation in Compound A. Thus, complete eradication (6-log reduction) of P. aeruginosa and MRSA were observed for all concentrations tested. No growth was observed on negative control plates. Therefore, the experimental results are valid.

[0549] Based on the data presented herein, the mean recovery of each test organism did not exceed a two-fold reduction from the corresponding control, and colony counts on plates inoculated with Compound A were within the USP 61 acceptance criteria (<20 CFU for an inputDocket No. G2093-7014WO

[0550] of <100 CFU). No microbial growth was observed on negative control plates or uninoculated Compound A plates. These findings confirm the validity of the test.

[0551] In accordance with USP 61 methods for microbiological examination, Compound A meets the acceptance criteria for absence of test microorganisms and is considered free from Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Escherichia coli, and Candida albicans.

[0552] Furthermore, after sterilization, Compound A demonstrated antibacterial efficacy against gram-negative (P. aeruginosa') and gram-positive (MRSA) human pathogens at all concentrations tested.

[0553] The phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. As used herein, the term “plurality” refers to two or more items or components. The terms “comprising,” “including,” “carrying,” “having,” “containing,” and “involving,” whether in the written description or the claims and the like, are open-ended terms, i.e., to mean “including but not limited to.” Thus, the use of such terms is meant to encompass the items listed thereafter, and equivalents thereof, as well as additional items. Only the transitional phrases “consisting of” and “consisting essentially of,” are closed or semi-closed transitional phrases, respectively, with respect to the claims. Use of ordinal terms such as “first,” “second,” “third,” and the like in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.

[0554] Having thus described several aspects of at least one embodiment, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Any feature described in any embodiment may be included in or substituted for any feature of any other embodiment. Such alterations, modifications, and improvements are intended to be part of this disclosure and are intended to be within the scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

[0555] Those skilled in the art should appreciate that the parameters and configurations described herein are exemplary and that actual parameters and / or configurations will depend onDocket No. G2093-7014WO

[0556] the specific application in which the disclosed methods and materials are used. Those skilled in the art should also recognize or be able to ascertain, using no more than routine experimentation, equivalents to the specific embodiments disclosed.

Claims

Docket No. G2093-7014WOCLAIMS1. A preparation comprising one or more peptides having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern, the one or more peptides being configured to self-assemble into a fibril formation, in a cosmetically acceptable carrier.

2. A preparation comprising one or more peptides having a sequence of [AY]N, [YA]M, Y[AY]N, or A[YA]M, where A is 1-3 amino acids selected from one or more of basic, neutral, aliphatic, aromatic, amphipathic, polar, and charged amino acids, Y is 1-3 hydrophobic amino acids, and N and M are between 1 and 10, the one or more peptides being substantially free of a turn sequence, in a cosmetically acceptable carrier.

3. A preparation comprising:one or more peptides having a sequence of any of SEQ ID NOS: 1-73 and 107, one or more peptides having a sequence having 1-4 substitutions of any of SEQ ID NOS: 1-73 and 107, orone or more peptides having a sequence of any of SEQ ID NOS: 1-73 and 107 or a sequence having 1-4 substitutions of any of SEQ ID NOS: 1-73 and 107 and further having a modification;in a cosmetically acceptable carrier.

4. The preparation of claim 1 or claim 2, wherein the one or more peptides comprise 6-18 amino acid residues;the hydrophobic amino acid residues are independently selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, threonine, tryptophan, and combinations thereof; and / orthe charged amino acid residues are independently selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, cysteine, arginine, lysine, histidine, aspartic acid, glutamic acid, and combinations thereof.Docket No. G2093-7014WO5. The preparation of claim 4, wherein the charged amino acid residues are positively charged amino acid residues.

6. The preparation of claim 4, wherein the charged amino acid residues are negatively charged amino acid residues.

7. The preparation of claim 2, wherein A is 1-3 uncharged polar amino acid residues.

8. The preparation of claim 1 or claim 2, wherein the one or more peptides further comprise a modification.

9. A preparation comprising:a fragment of a peptide of any of SEQ ID NOS: 75-97;a fragment of a peptide having a sequence having 1-4 substitutions of any of SEQ ID NOS: 75-97; ora fragment of a peptide of any of SEQ ID NOS: 75-97 or a fragment of a peptide having a sequence having 1-4 substitutions of any of SEQ ID NOS: 75-97 and further having a modification,in a cosmetically acceptable carrier.

10. The preparation of claim 9, wherein the fragment of the peptide of any of SEQ ID NOS:75-97 is a peptide having a sequence of SEQ ID NO: 74.

11. The preparation of claim 3 or any of claims 8-9, wherein the modification is a bioactive functional group, linker, spacer, or terminal modification.

12. The preparation of claim 3 or any of claims 8-9, wherein the modification is a bioactive functional group having a sequence of any of SEQ ID NOS. 98-106.Docket No. G2093-7014WO13. The preparation of claim 3 or any of claims 8-9, wherein the modification is terminal modification selected from acetylation, amidation, free carboxyl, PEGylation, lipidation, glycosylation, cyclization, and combinations thereof.

14. The preparation of any of claims 1-3 or 9, wherein the one or more peptides have a free amine at the N-terminus, a free carboxyl group at the C-terminus, or both.

15. The preparation of any of claims 1-3, wherein the one or more peptides comprises at least one glutamic acid residue.

16. The preparation of any of claims 1-3 or 9, wherein the preparation is formulated for topical administration.

17. The preparation of claim 16, wherein the preparation is formulated as an aqueous solution, gel, lotion, ointment, cream, serum, oil, salve, and / or solid.

18. The preparation of claim 16, wherein the preparation is formulated for administration by spray, aerosol, dropper, tube, ampule, or syringe.

19. The preparation of claim 16, wherein the preparation is formulated as a film, membrane, sheet, barrier dressing, or impregnated material.

20. The preparation of any of claims 1-3 or 9, wherein the preparation consists of or consists essentially of the one or more peptides in the cosmetically acceptable carrier.

21. The preparation of any of claims 1-3 or 9, wherein the preparation is substantially free of one or more of preservatives, fillers, bulking agents, fragrances, or colorants.

22. The preparation of any of claims 1-3 or 9, wherein the preparation is formulated for parenteral administration.Docket No. G2093-7014WO23. The preparation of any of claims 1 -3 or 9, wherein the one or more peptides are at least 70% purified.

24. The preparation of any of claims 1-3 or 9, wherein the one or more peptides comprise acetate and / or citrate counterions.

25. The preparation of any of claims 1-3 or 9, wherein the one or more peptides are free of chloride counterions.

26. The preparation of any of claims 1-3 or 9, wherein the preparation comprises between 0.01% w / v and 10.0% w / v of the one or more peptides.

27. The preparation of claim 26, wherein the preparation comprises between 0.25% w / v and 0.5% w / v of the one or more peptides.

28. The preparation of any of claims 1-3, wherein the one or more peptides have a net charge of from -10 to +11.

29. The preparation of claim 28, wherein the one or more peptides have a net charge of +3 to +4.

30. The preparation of any of claims 1-3 or 9, wherein the preparation is sterile.

31. The preparation of claim 30, wherein the preparation is sterilized by autoclave or steam sterilization.

32. The preparation of any of claims 1-3 or 9, wherein the preparation has a pH between 3 and 8.

33. The preparation of claim 32, wherein the preparation has a pH between 5.5 and 6.5.

34. The preparation of any of claims 1-3 or 9, wherein the preparation further comprises an effective amount of one or more of a cationic or anionic salt, a dermatologically compatibleDocket No. G2093-7014WObuffer, a zwitterionic buffer, an organic acid and / or salt thereof, a chelating buffer, or a combination thereof.

35. A method of providing cosmesis, comprising administering an effective amount of a preparation of any of claims 1-34 to a target tissue of a subject.

36. The method of claim 35, wherein administration improves skin integrity, improves skin surface topology, reduces or prevents degradation of collagen in skin of the subject or increases collagen content in skin of the subject, reduces or prevents inflammation in skin or a hair follicle, prevents, limits, or inhibits progression of an appearance or effect of aging in the skin, prevents, limits, or inhibits skin inflammation, prevents, limits, or inhibits injury to skin integrity or condition, substantially maintains a state of skin integrity or condition, prevents, limits, or inhibits a topographical change of a cutaneous layer of skin.

37. The method of claim 35, wherein administration treats or prevents skin wrinkles and / or treats or prevents a change in skin pigmentation.

38. The method of claim 35, wherein administration promotes firmness, hydration, elasticity, radiance, tone evenness, visual smoothness, or tactile smoothness associated with skin of the subject.

39. The method of claim 35, wherein the target tissue is an integumental tissue selected from an epidermal, dermal, or hypodermal tissue.

40. The method of claim 39, wherein the integumental tissue is on one or more of the face, forehead, eye region, cheek, nose, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, calf, thigh, or buttocks of the subject.

41. The method of claim 35, wherein the preparation is administered topically.